POPULARITY
Categories
15 episodes with drug administration fda
26 episodes with drug administration fda
32 episodes with drug administration fda
35 episodes with drug administration fda
16 episodes with drug administration fda
19 episodes with drug administration fda
12 episodes with drug administration fda
7 episodes with drug administration fda
8 episodes with drug administration fda
8 episodes with drug administration fda
11 episodes with drug administration fda
6 episodes with drug administration fda
7 episodes with drug administration fda
7 episodes with drug administration fda
5 episodes with drug administration fda
9 episodes with drug administration fda
13 episodes with drug administration fda
4 episodes with drug administration fda
6 episodes with drug administration fda
5 episodes with drug administration fda
5 episodes with drug administration fda
16 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
3 episodes with drug administration fda
5 episodes with drug administration fda
6 episodes with drug administration fda
7 episodes with drug administration fda
4 episodes with drug administration fda
10 episodes with drug administration fda
3 episodes with drug administration fda
5 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
11 episodes with drug administration fda
3 episodes with drug administration fda
3 episodes with drug administration fda
5 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
4 episodes with drug administration fda
2 episodes with drug administration fda
2 episodes with drug administration fda
4 episodes with drug administration fda
3 episodes with drug administration fda
This interview is disseminated on behalf of GT Biopharma. GT Biopharma (NASDAQ: GTBP) recently received approval from the U.S. Food and Drug Administration (FDA) for a new investigational drug trial for the solid tumor cancer treatment GTB-3650, as the race to develop a cure for cancer intensifies and the solid tumor market grows to $362 billion.Executive Chairman and Chief Executive Officer Michael Breen shares more details about the company's expectations and success indicators for the basket trial of the new medication, as well as upcoming milestones for 2026.Explore GT Biopharma: https://www.gtbiopharma.com/Watch the full YouTube interview here: https://youtu.be/VtISaFICJ5gAnd follow us to stay updated: https://www.youtube.com/GlobalOneMedia
In this episode of the Ageless Future podcast, host Cade Archibald sits down with Dr. Brandon Burke to explore his journey from building multiple successful orthodontic practices to stepping into a new chapter focused on coaching and personal development. Brandon shares how growing up in a small Utah town shaped his drive, what it looked like to build a practice from scratch during the recession, and the moment he realized his achievements weren't the same as fulfillment. The conversation dives into themes of identity, burnout, resilience, and “unbecoming”—letting go of external validation to reconnect with purpose, emotional awareness, and grounded leadership in family and community. Brandon closes with a message about choosing to live as a creator rather than a victim, and how his most difficult season became the turning point that helped him realign his life.BRANDON BURKE:Websites: gettinlostisbeingfound.com and more-than-love.comIG: https://www.instagram.com/gettinlostisbeingfound/FB: @safetobeseenTikTok: https://www.tiktok.com/@gettinlostisbeing/YouTube: Safe To Be Seen~ https://youtube.com/@safetobeseenPodcast: https://podcasts.apple.com/us/podcast/safe-to-be-seen/id1817823527AGELESS FUTURE:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Dr. Roger McFillin argues that Western allopathic medicine and psychiatry have medicalized normal human suffering by reducing emotions to biological or chemical reactions, turning symptom checklists into fixed identities, and sustaining a drug-driven "sick care" system that creates lifelong customers. He contrasts this with viewing emotions as powerful energy meant to be moved into creation and transformation, cites psychoneuroimmunology, and warns that suppressing fear and distress with pharmaceuticals can worsen long-term outcomes. The conversation covers exposure-based approaches to unlearn fear, the role of media, social media, and advertising in provoking fear and keeping people in an unconscious "drift" state, and the importance of intentional stillness, solitude (distinct from loneliness), prayer or silent meditation, and reducing phone use—especially at the start of the day—to become more conscious and intentional. McFillin discusses how diagnostic labels like depression and anxiety shape identity, limit choices, and contribute to chronicity and polypharmacy. He contrasts PTSD with post-traumatic growth, emphasizing processing trauma memories, facing avoided situations, challenging overgeneralized threat beliefs, and practicing forgiveness and self-compassion while also taking ownership where appropriate. They also discuss the perceived harms of the "toxic masculinity" concept, men's wellbeing, the loss of wise elders, and how men often bond and cope through shared activities. Dr. Roger McFillin is a clinical psychologist and trauma recovery expert who challenges the medicalization of normal human emotions. With a focus on emotional resilience and personal growth, he specializes in exposure therapy and psychoneuroimmunology, exploring the connection between mind, emotions, and immune health. Dr. McFillin advocates for self-regulation and transforming emotional energy into healing, critiquing the overuse of pharmaceuticals in modern mental health treatment. Through his Substack, Radically Genuine, and podcast, Dr. McFillin educates individuals on overcoming fear, achieving stillness, and reconnecting with their true selves. His work empowers people to shift from a victim mindset to one of active growth, using trauma as a catalyst for resilience and positive change. Science & Medicine Psychoneuroimmunology Overview & science (NIH): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3130991/ Exposure Therapy Wikipedia overview: https://en.wikipedia.org/wiki/Exposure_therapy Cleveland Clinic explanation: https://my.clevelandclinic.org/health/treatments/25067-exposure-therapy Anxiety & OCD exposure-based approaches (IOCDF): https://iocdf.org/about-ocd/treatment/erp/ Heart Coherence HeartMath Institute overview: https://www.heartmath.org/heart-coherence/ Psychiatric Diagnosis & DSM Critique of DSM and diagnostic categories: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4195174/ Psychiatric diagnosis controversies: https://www.apa.org/monitor/2013/04/diagnosis Psychology & Healing Post-Traumatic Growth vs. PTSD Scientific overview of post-traumatic growth: https://www.apa.org/monitor/2014/01/psychological-recovery Journal article on PTG vs PTSD: https://www.sciencedirect.com/science/article/abs/pii/S0272735814000412 Forgiveness and Healing Psychology Today on forgiveness: https://www.psychologytoday.com/us/basics/forgiveness Research evidence on forgiveness and wellbeing: https://journals.sagepub.com/doi/10.1177/1745691614568356 Self‑Healing Practices Grounding / Earthing What is grounding/earthing? https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4378297/ PEMF (Pulsed Electromagnetic Field) Therapy Basics of PEMF therapy: https://www.health.harvard.edu/pain/pulsed-electromagnetic-field-therapy Meditation & Stillness Mindfulness & stillness research: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6422583/ Psychology Today on solitude and healing: https://www.psychologytoday.com/us/blog/hide-and-seek/201209/finding-solitude-its-benefits-and-challenges Cultural & Media Influence Mind Control & Fear Provocation The psychology of fear in media messaging: https://www.frontiersin.org/articles/10.3389/fpsyg.2020.566245/full Media influence and persuasion research: https://www.communicationtheory.org/agenda-setting-theory/ Toxic Masculinity Research overview on toxic masculinity: https://www.apa.org/advocacy/health-men/guidelines What toxic masculinity means: https://www.psychologytoday.com/us/blog/the-masculine-mind/201802/what-toxic-masculinity Dr. Roger McFillin Content Substack (Radically Genuine): https://drmcmillan.substack.com Show Notes 00:00 Emotions as Energy 00:33 Medicalizing Suffering 02:44 Exposure Beats Suppression 05:18 Fear and Mind Control 10:21 Stillness vs Loneliness 14:47 Simple Stillness Practices 20:12 Morning Intention Rituals 25:56 Labels and Identity Traps 31:26 Systemic Treatment Harm 32:53 Depression Label Identity 35:08 Sadness Versus Pathology 36:10 PTSD And Growth 38:24 Processing Trauma Fully 41:44 Practical Recovery Steps 45:48 Forgiveness And Ownership 50:37 Toxic Masculinity Debate 56:12 Men Friendship And Elders 01:01:05 Closing Plugs Farewell 38:24 How PTSD Develops 41:44 Practical Trauma Recovery 45:48 Forgiveness and Ownership 50:37 Toxic Masculinity Debate 56:12 Male Friendship and Elders 01:01:05 Closing and Where to Follow The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode of Creating Your Ageless Future, Regan Archibald offers a high-level, educational walkthrough of regenerative medicine—covering commonly discussed categories like biologics, cellular therapies, signaling molecules, PRP, and exosomes—while emphasizing the importance of separating marketing from evidence. He shares why public interest has accelerated (including demographic and cultural factors), describes how product variability and regulatory action have shaped the landscape, and explains why research concepts like cell sourcing, handling, and testing are central to quality and safety discussions. Regan also outlines how teams often approach decision-making in this space—using diagnostics, careful sourcing, and lifestyle context—while cautioning against one-size-fits-all claims and DIY experimentation.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
"Because the premise of immune checkpoint blockade centers around elevating the immune function, we should always take a great deal of caution around those patients who have high immune risks. Those include patients with autoimmune disorders. That's one of our biggest questions that we ask, usually every consult that we're seeing with solid tumor. 'Do you have any history of autoimmune disorders? Tell me a little bit more about it. Is it being treated? What are your symptoms like?' And then also patients who have undergone organ transplants. Now, interestingly, this does include stem cell transplants," Kelsey Finch, PharmD, BCOP, oncology pharmacist practitioner at Columbus Regional Health in Indiana, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about checkpoint inhibitors. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 20, 2027. Kelsey Finch has disclosed a speakers bureau relationship with AstraZeneca. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to checkpoint inhibitors in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 273: Updates in Chemotherapy and Immunotherapy Episode 174: Administer Pembrolizumab Immunotherapy With Confidence Episode 139: How CAR and Other T Cells Are Revolutionizing Cancer Treatment ONS Voice articles: Here's Why Oncology Nurses Are Pivotal in Managing Immune-Related Adverse Events Make Subcutaneous Administration More Comfortable for Your Patients Nursing Considerations for ICI-Related Myocarditis Oncology Nurses Navigate the Changing Landscape of Immuno-Oncology Postdischarge ICI Patient Education Eliminates Hospital Readmissions Shorter Administration Times Still Require High-Acuity Care ONS Voice oncology drug reference sheets: Dostarlimab-Gxly Nivolumab and Hyaluronidase-Nvhy Nivolumab and Relatlimab-Rmbw Pembrolizumab and Berahyaluronidase Alfa-Pmph Retifanlimab-Dlwr Toripalimab-Tpzi ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Guide to Cancer Immunotherapy (second edition) ONS course: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ Clinical Journal of Oncology Nursing articles: Immune Checkpoint Inhibitor–Related Myocarditis: Recognition, Surveillance, and Management Immune Checkpoint Inhibitor Therapy: Key Principles When Educating Patients Triple M Syndrome: Implications for Hematology-Oncology Advanced Practice Providers ONS Huddle Cards: Checkpoint Inhibitors Immunotherapy ONS Learning Libraries: Genomics and Precision Oncology Learning Library Immuno-Oncology Learning Library Drugs@FDA package inserts National Comprehensive Cancer Network homepage OncoLink: All About Immunotherapy To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Before immune checkpoint blockade, the two-year overall survival rate in metastatic melanoma was hovering around 10%. After these agents came to market, depending on the trial and the agents used, that number actually increased to about 50%–65%. So, five times the amount of patients were actually living at the two-year mark. Not surprisingly, studies then exploded across several tumor types, leading to approvals in all sorts of cancers, mostly in the solid tumor. But there are a couple hematologic as well. Lung cancer, kidney cancer, head and neck, Hodgkin lymphoma, hepatocellular, the list goes on. So, it's really just transforming the stage IV setting across all tumors, specifically from uniformly fatal prognosis to one where durable responses and long-term survival is also possible." TS 3:03 "There are four different mechanisms officially being used in therapies that are approved by the U.S. Food and Drug Administration (FDA). Those are cytotoxic T-lymphocyte–associated protein 4, programmed cell death protein 1, and programmed cell death ligand 1, which I'm counting as two different mechanisms, even though they somewhat work together. And lymphocyte-activation gene 3 is the fourth one that's in there. So, all these mechanisms impact the T cell in our immune system. The T cell is traditionally responsible for protecting our body from harmful things like bacteria, viruses, and cancer. When the tumor binds to cytotoxic T-lymphocyte–associated protein 4 receptors, that happens on the T cell itself. And that inhibits the activation of the T cells, essentially allowing that tumor to then live. So when developing medications that block this receptor, they noted an added benefit that it actually increased the T-cell proliferation as well as keeping that T cell active. So not only are we not blocking the T cells, we're making them more productive." TS 5:38 "If you have a chance of any sort of tissue rejection, specifically with allogeneic stem cell transplants or where we see that focusing on it, there's a little bit of controversy, mixed bag on opinions as far as autologous stem cell transplants. But it's best to at least exercise a little bit of caution. If they have a chance of organ rejection, is that worth the risk of the therapy that we're looking to give? And then, patients with HIV, any sort of immunologic concerns at baseline that we could potentially worsen." TS 14:37 "As a rule of thumb, with immune checkpoint blockade, regardless of what mechanism you're looking at, if something in your body can get inflamed, that can wind up as an adverse event. So, whenever I talk to my patients, the key word is anything ending in '-itis.' ... The most common adverse events that we end up seeing are dermatitis and hypothyroidism. Immune checkpoint blockade can cause both hyper- and hypothyroidism. Very often, we actually start in the hyper- and then end up, for lack of better words, burning out the thyroid, ultimately leading to a sustained hypothyroidism." TS 18:34 "The half-life of immune checkpoint inhibitors is usually around 30 days, meaning that once these agents are given, the drug will be in the patient's system for up to five months. Specifically, it will probably build month to month, so often we don't even see a lot of our adverse events until month three or four. Usually, when we're that far into treatment, we're not looking for new adverse events in things like chemotherapy. But these drugs do build over time." TS 24:28 "As far as safe handling is concerned, these agents are not chemotherapy. That makes drug compounding and administration pretty straightforward. When looking at the follow-up care, the most important thing, in my opinion, is to engage in meaningful dialogue with your patients. A lot of the side effects can be nonspecific. So, really listening to the patient and evaluating changes in their lifestyle, I think it'll get you far. We usually hark in on the new, worsening, or persistent whenever we're talking to patients because they'll be looking for things as well. So, just having a dialogue of how their life has changed can certainly help." TS 26:17
This episode explores tadalafil (Cialis) as a potential longevity drug, though no randomized human trials prove it extends lifespan. Cialis works by blocking PDE5, enhancing nitric oxide signaling, and improving blood flow through vasodilation. Originally approved for pulmonary hypertension, it's also used for erectile dysfunction and BPH. Its 36-hour half-life makes it superior to Viagra for continuous longevity effects. The host frames vascular aging and endothelial dysfunction as key drivers of age-related diseases (heart disease, stroke, dementia, kidney disease). Observational data shows Cialis users have 44% lower mortality, fewer cardiovascular events, reduced dementia risk, and lower mortality in diabetics. Additional benefits include improved cardiac function, reduced infarct size, arrhythmia suppression, and regression of left ventricular hypertrophy. A 2024 meta-analysis found it lowers hemoglobin A1C, possibly via improved microvascular perfusion, insulin sensitivity, and mitochondrial function. Cialis crosses the blood-brain barrier and may improve neurovascular coupling and hippocampal plasticity, potentially benefiting those with or at risk of dementia. Safety is generally good with long-term daily use (2.5–5 mg), though cautions include avoiding use with nitrates, low blood pressure, or certain retinal disorders. Common side effects are headache, nasal congestion, and acid reflux. The host recommends consulting a doctor and references potential synergy with telmisartan. Tadalafil (Cialis) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a604008.html](https://medlineplus.gov/druginfo/meds/a604008.html) Sildenafil (Viagra) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a699015.html](https://medlineplus.gov/druginfo/meds/a699015.html) Key mechanisms mentioned Nitric Oxide (NO) — NCBI Bookshelf: [https://www.ncbi.nlm.nih.gov/books/NBK554485/](https://www.ncbi.nlm.nih.gov/books/NBK554485/) Cyclic GMP (cGMP) — NCBI Bookshelf: [https://www.ncbi.nlm.nih.gov/books/NBK542234/](https://www.ncbi.nlm.nih.gov/books/NBK542234/) Conditions mentioned in the episode Benign Prostatic Hyperplasia (BPH) — MedlinePlus: [https://medlineplus.gov/benignprostatichyperplasia.html](https://medlineplus.gov/benignprostatichyperplasia.html) Pulmonary Arterial Hypertension (PAH) — MedlinePlus: [https://medlineplus.gov/pulmonaryhypertension.html](https://medlineplus.gov/pulmonaryhypertension.html) Blood pressure drug mentioned Telmisartan — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a601249.html](https://medlineplus.gov/druginfo/meds/a601249.html) Other longevity / comparison drugs mentioned Metformin — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a696005.html](https://medlineplus.gov/druginfo/meds/a696005.html) Sirolimus (Rapamycin) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a602026.html](https://medlineplus.gov/druginfo/meds/a602026.html) Side-effect helper mentioned Ibuprofen (Advil) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a682159.html](https://medlineplus.gov/druginfo/meds/a682159.html) Dementia meds mentioned Donepezil (Aricept) — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a697032.html](https://medlineplus.gov/druginfo/meds/a697032.html) Amantadine — MedlinePlus drug info: [https://medlineplus.gov/druginfo/meds/a682064.html](https://medlineplus.gov/druginfo/meds/a682064.html) Lab markers mentioned Hemoglobin A1C (HbA1c) test — MedlinePlus lab test: [https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/](https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/) Insulin in blood test — MedlinePlus lab test: [https://medlineplus.gov/lab-tests/insulin-in-blood/](https://medlineplus.gov/lab-tests/insulin-in-blood/) People referenced (where the claims were mentioned) Huberman Lab (Dr. Andrew Huberman) — site: [https://www.hubermanlab.com/](https://www.hubermanlab.com/) Clip about low-dose tadalafil (2.5–5mg) — X post: [https://x.com/tbpn/status/2022350426394534334](https://x.com/tbpn/status/2022350426394534334) Bryan Johnson (Blueprint) — site: [https://blueprint.bryanjohnson.com/](https://blueprint.bryanjohnson.com/) Dr. David Sinclair (Harvard profile) — site: [https://sinclair.hms.harvard.edu/people/david-sinclair](https://sinclair.hms.harvard.edu/people/david-sinclair) Show Notes 00:00 Welcome to the Hart2Heart Podcast. 01:56 What Cialis Is: PDE5 Inhibition, cGMP & Nitric Oxide Explained 03:43 Approved Uses & Origin Story: Pulmonary Hypertension, ED, and BPH 05:33 Why Cialis Over Viagra: 36-Hour Half-Life & 24/7 Vascular Benefits 06:52 Vascular Aging 101: Endothelium, Perfusion, and Why It Drives Disease 11:14 What the Human Data Shows: Observational Evidence for Mortality, CVD & Dementia 13:04 Mechanisms Deep Dive: Heart Protection, Heart Failure, and Anti-Atherosclerosis 15:02 Cialis for Diabetics: Lowering A1C and Improving Insulin Sensitivity 16:21 Brain Effects: Blood–Brain Barrier, Neurovascular Coupling & Dementia Potential 18:21 Safety, Who Should Avoid It, and Daily Longevity Dosing (2.5–5 mg) + Wrap-Up The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Regan Archibald welcomes the audience and shares updates from recent travel before outlining how his “Ageless Future operating system” uses lab data to guide a more intentional health strategy. He emphasizes starting with clarity about goals and symptoms, then looking for patterns and trends across markers rather than relying only on standard reference ranges or single numbers. He discusses examples of deeper testing beyond common basics, the value of tracking data over time, and the importance of viewing markers in context—such as sleep, stress, nutrition, and training—so decisions are based on a fuller picture. He also highlights how inflammation and hormone-related markers can be considered as part of an integrated review, and closes by encouraging viewers to stay current with labs and contact the office or website to get testing scheduled if it's been more than six months.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Dinesh Patel, PhD, CEO of Protagonist Therapeutics, discusses the New Drug Application (NDA) submission to the US Food and Drug Administration (FDA) for rusfertide to treat adults with polycythemia vera (PV).PV is characterized by excess red blood cells in the bloodstream, increasing the risk for blood clots. Most cases of PV are acquired and occur more frequently in men than in women. The condition has been associated with genetic changes in the JAK2 and TET2 genes. Rusfertide is an investigational first-in-class subcutaneously administered hepcidin mimetic peptide designed to regulate iron homeostasis and red blood cell production to control hematocrit levels in patients with PV.The NDA submission is based on positive 32-week primary analysis and 52-week results from the phase 3, global, randomized, placebo-controlled VERIFY clinical trial (NCT05210790). In this study, patients receiving rusfertide plus standard of care therapy demonstrated a substantially higher response rate compared to placebo plus standard of care, including durable hematocrit control, a reduction in phlebotomy requirements and improvement in pre-specified patient reported outcome endpoints.Rusfertide has received Breakthrough Therapy Designation, Orphan Drug Designation, and Fast Track Designation from the FDA.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events and decisions in the industry that are shaping the path forward for drug development and patient care.The U.S. Food and Drug Administration (FDA), an agency often at the center of pharmaceutical innovation and scrutiny, has recently made several noteworthy decisions. These decisions not only point to the ongoing regulatory challenges but also highlight scientific advancements within the field.One of the key updates involves the FDA's decision to reject Disc's drug bitopertin, which was intended for the treatment of erythropoietic protoporphyria, a rare blood disease. Despite receiving a national priority voucher for expedited review, the FDA ultimately concluded that the clinical data did not sufficiently support regulatory approval. This decision underscores the FDA's commitment to maintaining rigorous standards even when expedited reviews are in play, emphasizing the necessity of robust clinical evidence for approval.Adding complexity to this situation is the internal dynamics within the FDA itself. Richard Pazdur, a long-standing official at the agency, recently stepped down, revealing disagreements with Commissioner Marty Makary over reducing the number of clinical trials required for new drug applications. Pazdur's departure after an influential 26-year tenure highlights ongoing debates within regulatory bodies on how to balance innovative approval pathways with ensuring safety and efficacy data.In another notable development, Moderna faced setbacks with its mRNA-1010 flu vaccine as the FDA declined to review it. This decision leaves American consumers without access to potentially more effective mRNA-based flu vaccines—a technology embraced by other countries for influenza treatment. This situation points to possible missed opportunities in leveraging cutting-edge vaccine technologies domestically, showcasing both the promise and regulatory complexities surrounding mRNA technology.These regulatory challenges unfold amid leadership changes and strategic shifts within health agencies. For instance, Jim O'Neill's departure from his role as acting director of the Centers for Disease Control and Prevention following Susan Monarez's abrupt ouster illustrates how leadership turbulence can impact policy consistency and strategic direction, potentially affecting how new health initiatives are prioritized and implemented.Meanwhile, companies like Vertex and CRISPR Therapeutics are ambitiously advancing gene therapy solutions such as Casgevy, signaling a broader trend towards personalized medicine and advanced biotechnological approaches. These efforts promise transformative impacts on patient care and reflect an industry-wide move towards precision medicine.Eli Lilly's substantial investment in orforglipron stock ahead of its anticipated approval further indicates confidence in their product pipeline amidst growing competition from Novo Nordisk's Wegovy pill abroad. This competitive landscape highlights increasing interest and investment in innovative treatments for metabolic diseases.Overall, these developments illustrate a dynamic interplay between scientific innovation, regulatory scrutiny, and strategic corporate maneuvers that shape healthcare's future. As companies push technological boundaries, regulators face ongoing challenges in adapting frameworks that ensure patient safety while fostering innovation. The outcomes of these processes will significantly influence not only patient access to cutting-edge therapies but also set precedents for future drug development and approval pathways. As these trends unfold, stakeholders across the industry must remain agile, informed, and collaborative to navigate this evolving landscape effectively.Looking back at 2025, it was a tSupport the show
In this podcast episode, an in-depth discussion is provided on the drug Telmisartan, commonly used for lowering blood pressure. The host elaborates on how it belongs to a class of medications known as angiotensin receptor blockers (ARBs) and stands out due to its 24-hour half-life and partial PPAR-gamma agonist activity. The episode explores Telmisartan's potential benefits for longevity, including its properties that reduce cardiovascular mortality, renal decline, and metabolic issues. It also compares Telmisartan with other ARBs and addresses its unique ability to improve myocardial efficiency, reduce arterial stiffness, and support neuroprotection. Detailed explanations are given on technical concepts such as pulse pressure and its relevance to arterial compliance, and the necessity to consult a doctor before taking the medication is emphasized. Telmisartan / ARBs (main topic) Telmisartan — MedlinePlus drug info: https://medlineplus.gov/druginfo/meds/a601249.html Blood pressure meds overview (includes ARBs): https://medlineplus.gov/bloodpressuremedicines.html Key mechanisms mentioned PPARγ (PPARG) — NCBI Gene: https://www.ncbi.nlm.nih.gov/gene/5468 Endothelium + nitric oxide (NO) — NCBI Bookshelf: https://www.ncbi.nlm.nih.gov/books/NBK534266/ Angiotensin / aldosterone / "fight-or-flight" Aldosterone test — MedlinePlus lab test: https://medlineplus.gov/lab-tests/aldosterone-test/ Sympathetic nervous system ("fight-or-flight") — Cleveland Clinic explainer: https://my.clevelandclinic.org/health/body/23262-sympathetic-nervous-system-sns-fight-or-flight Lab tests mentioned in the episode Fasting insulin ("Insulin in Blood") — MedlinePlus lab test: https://medlineplus.gov/lab-tests/insulin-in-blood/ Hemoglobin A1C (HbA1c) — MedlinePlus lab test: https://medlineplus.gov/lab-tests/hemoglobin-a1c-hba1c-test/ C-reactive protein (CRP) — MedlinePlus lab test: https://medlineplus.gov/lab-tests/c-reactive-protein-crp-test/ Arterial stiffness / pulse pressure (longevity framing) Pulse pressure & arterial stiffness as risk predictors — PubMed: https://pubmed.ncbi.nlm.nih.gov/11224702/ Visceral fat resource mentioned Dr. Sean O'Mara website: https://drseanomara.com/ Show Notes 00:00 Welcome to the Hart2Heart Podcast. 01:22 Understanding Angiotensin and Its Effects 02:14 How ARBs Work and Their Benefits 03:00 Unique Properties of Telmisartan 03:36 Comparing Telmisartan with Other ARBs 04:44 Telmisartan's Impact on Endurance and Fat Loss 05:59 Telmisartan and Cardiovascular Health 09:57 Blood Pressure Basics and Pulse Pressure 18:54 Telmisartan's Role in Longevity and Dosing 27:28 Conclusion and Final Thoughts The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode, Regan Archibald breaks down why emotional health isn't “soft”—it's biochemical. He introduces the EPIC triggers (Emotions, Pain, Infections, Chemicals) and focuses on how emotions leave a measurable chemical trail that can either support health or accelerate inflammation. Using examples like anger increasing inflammatory signaling (including IL-6) and gratitude/joy supporting nitric oxide and vascular function, Regan explains how repeated emotional patterns can rewire the brain, shape immune behavior, and even override diet, exercise, and supplements if left unmanaged. The takeaway: practice the pause, choose your response, and build gratitude and connection on purpose. Consistency in emotional regulation can shift physiology toward resilience, recovery, and better long-term health.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
A review by the U.S. Food and Drug Administration (FDA) identified 51 PFAS in 1,744 cosmetic products. Among the 25 most-used PFAS, 19 lacked sufficient safety data for assessment The most common PFAS in European makeup were polytetrafluoroethylene (PTFE) in 26% of PFAS-positive products and perfluorodecalin in 22%, both used to soften skin In a 2021 study, researchers discovered that 82% of waterproof mascaras and over 60% of tested lipsticks and foundations contained high levels of fluorine, indicating the presence of hidden PFAS Several top brands like Urban Decay, Inglot, L'Oréal, Maybelline, Burt's Bees, and Bare Minerals have faced lawsuits or investigations for PFAS contamination despite being marketed as "natural" or "clean" While the FDA lacks a national ban, U.S. states are now leading the shift toward PFAS-free beauty products — nine states have passed or scheduled bans on intentionally added PFAS in cosmetics through 2032
Kathleen Sanzo, J.D. is Co-Chair of Morgan Lewis' life sciences industry team. She centers her practice on regulatory and compliance issues connected to U.S. Food and Drug Administration (FDA)-regulated products. She leads and counsels clients on all legal and regulatory issues concerning food, dietary supplements, and cosmetic product manufacture, approval, marketing, and distribution; food, drug, and device compliance and enforcement matters; and consumer product issues regulated by the U.S. Consumer Product Safety Commission and state enforcement agencies, among other areas. A frequent author and co-author on publications related to FDA matters, Kathleen regularly speaks on these issues at industry events. She serves as Vice Chair of the Consumer Product Regulation Committee of the American Bar Association Section of Administrative Law and Regulatory Practice, and is a member of the Food and Drug Law Institute's Medical Products Committee. In this episode of Food Safety Matters, we speak with Kathy [32:33] about: Why FDA chose a voluntary approach to phasing out synthetic food dyes, the implications of this approach, and industry's response Why state-level food additive restrictions are outpacing federal action How the emerging patchwork of state laws creates significant operational and legal challenges for food manufacturers nationwide The expected supply chain impacts of phasing out synthetic dyes The legal risks companies face, from state enforcement to labeling, false advertising claims, and product liability How companies can prepare by monitoring legislation, securing dependable ingredient suppliers, updating labels, and planning consumer communication How state actions on additives may influence consumer expectations, spur industry innovation, and shape food policy over the next decade. News and Resources News FDA Releases Human Foods Program Priority Deliverables and Guidance Agenda for 2026 [5:48] FDA Testing Pinpoints Contaminated Ingredient in Infant Botulism Outbreak [17:44] EFSA Sets Safety Thresholds for Cereulide Toxin in Infant Formula [19:43] EFSA to Advise on Cereulide Levels in Infant Formula Following Global Recall UK Mother's Allegation that Recalled Nestlé Formula Sickened her Baby is Unconfirmed Experts Share Lessons from a Successful Listeria 'Seek and Destroy' Process [23:36] FDA to Hold Virtual Public Meeting on Food Allergen Thresholds, Releases Event Materials [29:44] Sponsored by: CINTAS We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
"You also want to deal with patient preferences. We do want to get their disease under control. We want to make them live a long, good quality of life. But do they want to come to the clinic once a week? Is it a far distance? Is geography a problem? Do they prefer not taking oral chemotherapies at home? We have to think about what the patient's preferences are to some degree and kind of incorporate that in our decision-making plan for treatments for relapsed and refractory myeloma," Ann McNeill, RN, MSN, APN, nurse practitioner at the John Theurer Cancer Center at Jersey Shore University Medical Center in Neptune, NJ, told Lenise Taylor, MN, RN, AOCNS®, TCTCN™, oncology clinical specialist at ONS, during a conversation about multiple myeloma treatment considerations. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by February 6, 2027. Ann McNeill has disclosed a speakers bureau relationship with Pfizer. This financial relationship has been mitigated. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the treatment of multiple myeloma. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Episode 398: An Overview of Multiple Myeloma for Oncology Nurses Episode 395: Pharmacology 101: Monoclonal Antibodies Episode 372: Pharmacology 101: Proteasome Inhibitors ONS Voice articles: Effective Care Transitions Are Essential for New Multiple Myeloma Treatments New Multiple Myeloma Treatments Present New Challenges in Side Effect Management Reduce Racial Barriers and Care Inequities for Black and African American Patients With Multiple Myeloma ONS Voice FDA approval alerts ONS Voice oncology drug reference sheets: Belantamab mafodotin-blmf Daratumumab Motixafortide Selinexor Clinical Journal of Oncology Nursing articles: Journey of a Patient With Multiple Myeloma Undergoing Autologous Stem Cell Transplantation Optimizing Transitions of Care in Multiple Myeloma Immunotherapy: Nurse Roles Oncology Nursing Forum article: Facilitators of Multiple Myeloma Treatment: A Qualitative Study ONS books: Hematopoietic Stem Cell Transplantation: A Manual for Nursing Practice (third edition) Multiple Myeloma: A Textbook for Nurses (third edition) ONS course: ONS Hematopoietic Stem Cell Transplantation™ ONS Huddle Cards: Financial Toxicity Hematopoietic Stem Cell Transplantation (HSCT) Monoclonal Antibodies ONS Hematology, Cellular Therapy, and Stem Cell Transplantation Learning Library American Society of Clinical Oncology (ASCO)–Ontario Health: Treatment of Multiple Myeloma Living Guideline International Myeloma Foundation: Clinical Trials Fact Sheets Clinical Trial Support Resource Library Multiple Myeloma Research Foundation resource: Treatments for Multiple Myeloma To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Typically for our first-line therapies, we use certain classes of drugs and some of them are proteasome inhibitors like bortezomib and carfilzomib. We also have IMiDs or immunomodulatory agents like thalidomide, lenalidomide, and pomalidomide. We have monoclonal antibodies, anti-CD38 monoclonal antibodies. Of course, we can never talk about treatment for myeloma without mentioning dexamethasone. It is an integral part of our treatment regimen. Most of our frontline therapies now are not just a single agent. They're not even doublets anymore. Typically, they're triplet therapies. And now in 2026, it's leaning more toward quadruplet therapies. By that, I mean you're taking a proteasome inhibitor, an immunomodulatory drug, dexamethasone, and an anti-CD38 monoclonal antibody all together to present patients with a good chance their induction therapy will lead to a good chance of them responding to treatment." TS 4:25 "[With] myeloma labs, there should be some indication after each cycle of therapy that the treatment is working. So, you don't have to do a whole myeloma panel, but maybe getting a monoclonal protein spike, maybe getting a free light chain assay, or maybe an immunoglobulin G or immunoglobulin A level, just to see if the treatment is working. So, those labs are crucial to determine whether the therapies are working. And again, the lab improvements usually correlate with the clinical presentation of the patient." TS 11:01 "There are active clinical trials ongoing with drugs like cell mods. Cell mods are the new oral anticancer agents for myeloma that have shown great promise with efficacy and safety profiles. And then there are other combinations that are showing a lot of promise. So, drugs that are already approved by the U.S. Food and Drug Administration (FDA). And I'm talking about pairing anti-CD38 monoclonal antibodies with bispecific T-cell engagers. If you do that, there has been some evidence that these combinations are very efficacious and responses are durable. And there are ongoing clinical trials and studies being done right now to see if these can be FDA-approved to pinpoint where they are as far as in comparison to other treatments." TS 20:10 "I always tell patients to try to participate in safe, and I want to stress safe, physical activity. So, I tell patients, the more you sit on the couch or you sit in the chair for most of the day, that unfortunately will make your pain worse. So, trying to get up and about and doing some physical activity, such as getting a physical therapy evaluation and a treatment program, no matter how passive or mild or gentle it is, can really help these patients with bone pain." TS 26:10 "I think it's important to realize that myeloma has had amazing advances in science, research and treatments. I think that all of these things coming together, all the science and clinical trials and everything like that, has led to a significant increase in overall survival of our patients, which ultimately is a great thing. We want patients to live longer and they're living longer with a very good quality of life. So, I think it's important to realize that myeloma is very well studied, very well researched, and it's still ongoing with many, many clinical trials." TS 36:04
In this episode of Ageless Future, Cade Archibald challenges the common view of muscle as merely cosmetic or mechanical, revealing instead that skeletal muscle functions as a powerful endocrine organ. He explains how contracting muscle releases signaling molecules called myokines that communicate with the brain, liver, immune system, and fat tissue—regulating metabolism, reducing inflammation, improving insulin sensitivity, and supporting cognitive health. Cade highlights why muscle is the body's largest glucose “sink,” making resistance training one of the most effective strategies for diabetes prevention and reversal. He also dives into the dangers of sarcopenia, emphasizing that muscle loss is not just weakness but a systemic breakdown that accelerates aging and increases vulnerability across every major body system. The episode closes with practical takeaways on preserving strength, building resilience, and treating muscle as one of the most essential foundations of longevity.RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of insightful updates that highlight the dynamic and rapidly evolving nature of these sectors, driven by scientific advancements, regulatory shifts, and strategic industry maneuvers.Starting with Merck, which is strategically planning for a post-Keytruda era, projecting over $70 billion in annual opportunities over the next decade. With Keytruda's patent expiration looming in 2028, Merck is actively expanding its portfolio through acquisitions and partnerships, focusing on oncology and immunology. These areas have been significantly impacted by Keytruda's success, and Merck's proactive approach aims to sustain growth and innovation beyond its current flagship product. During their 2025 full-year earnings call, CEO Robert Davis emphasized their expansive pipeline, highlighting recent strategic deals as pivotal to Merck's robust pipeline—the broadest it has been in years—signaling long-term growth through diversified therapeutic areas and innovative drug candidates.The U.S. Food and Drug Administration (FDA) is making waves with its regulatory approach to CAR-T cell therapies for autoimmune diseases. This shift reflects an increasing recognition of the potential these therapies hold for transforming treatment paradigms for conditions like lupus and multiple sclerosis. By offering a more flexible regulatory framework, the FDA is encouraging innovation while maintaining a focus on patient safety.In other regulatory news, AstraZeneca faces a setback with the FDA's rejection of its subcutaneous version of Saphnelo for lupus. The decision underscores the challenges associated with developing more patient-friendly administration methods for biologics. However, AstraZeneca remains optimistic about achieving a quick turnaround in the approval process, which could enhance patient adherence by offering a self-administered alternative to intravenous infusions.Sanofi finds itself in the spotlight after CEO Paul Hudson was sanctioned by the UK's Prescription Medicines Code of Practice Authority for making overly ambitious claims about Pfizer's RSV vaccine. This incident illustrates the competitive nature of vaccine procurement and underscores the importance of accurate communication by pharmaceutical leaders.In Massachusetts, Thermo Fisher Scientific is reducing its workforce with the closure of its Franklin site, impacting around 200 employees. This move is part of broader strategic realignments within the industry aimed at optimizing operations and focusing resources on high-growth areas.Acadia Pharmaceuticals faces potential rejection by the European Union for its drug trofinetide intended for Rett syndrome. This highlights ongoing challenges in gaining approval for treatments targeting rare diseases, despite their significant unmet needs.Meanwhile, GSK plans to lay off up to 350 R&D workers across the U.S. and UK as part of efforts to streamline operations and focus on core therapeutic areas. Such layoffs reflect broader industry trends toward consolidation and efficiency amid rising R&D costs.On a more promising note, Pfizer's GLP-1 receptor agonist has demonstrated significant results in a Phase 2b trial for weight loss, validating their substantial investment in this area. The drug's potential to offer competitive weight loss results with monthly dosing positions it as a strong contender in the obesity treatment market. Additionally, Pfizer continues to accelerate its efforts in obesity treatment with promising mid-stage trial results for PF-3944, showing up to a 12.3% weight loss at 28 weeks. This suggests Pfizer is keen on expanding its presence in obesity management through strategic clinical development as competition within this therapeutic area intensifies.The U.S. Department of Health and HumanSupport the show
"Radioimmunoconjugates work through a dual mechanism that combines immunologic targeting with localized radiation delivery. The monoclonal antibody components bind to specific tumor-associated antigens such as CD20, expressed on malignant B cells. Once found, the attached radioisotope delivers beta radiation directly to the tumor, causing DNA damage and cell death," Sabrina Enoch, MSN, RN, OCN®, CNMT, NMTCB (CT), theranostics clinical specialist at Highlands Oncology in Rogers, AR, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about radioimmunoconjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.25 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by January 30, 2027. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of radioimmunoconjugates in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 377: Creating and Implementing Radiopharmaceutical Policies and Procedures Episode 301: Radiation Oncology: Side Effect and Care Coordination Best Practices Episode 298: Radiation Oncology: Nursing's Essential Roles ONS Voice articles: Interprofessional Collaboration Reduces Time to Neutropenia Antibiotic Administration Radiopharmaceuticals and Theranostics Offer New Options for Oncology Nurses to Transform Cancer Care Radiopharmaceuticals Pack a One-Two Punch Against Cancer Safety Is Key in Use of Radiopharmaceuticals Telehealth Has Value During Radiotherapy, Patients Say ONS Voice oncology drug reference sheets: Lutetium Lu 177 dotatate Lutetium Lu 177 vipivotide tetraxetan Radium 223 dichloride Sodium iodide-131 Strontium chloride Sr-89 ONS books: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) Manual for Radiation Oncology Nursing Practice and Education (fifth edition) ONS courses: ONS/ONCC® Chemotherapy Immunotherapy Certificate™ ONS/ONCC® Radiation Therapy Certificate™ Clinical Journal of Oncology Nursing articles: Radiopharmaceutical Safety: Making It Easy Targeted Radionuclide Therapy: A Theranostic Approach to Cancer Therapy ONS Huddle Cards: Radiobiology Radiopharmaceuticals ONS Learning Libraries: Immuno-Oncology Radiation ONS Symptom Interventions for Prevention of Bleeding Drugs@FDA package inserts To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Radioimmunoconjugates are a specialized subset of radiopharmaceuticals designed to combine the specificity of monoclonal antibodies with the cytotoxic power of radiation. ... Early development focused on B-cell malignancies, particularly non-Hodgkin lymphoma." TS 1:51 "An important concept for nurses to understand is the crossfire effect, where radiation can affect nearby tumor cells, even though not every cell expressed has the target antigen. This helps explain why these agents can be effective even in heterogeneous tumors." TS 3:40 "At present, 90 Y-ibritumomab tiuxetan is the only radioimmunoconjugate approved by the U.S. Food and Drug Administration (FDA) in clinical use. Historically, iodine-131 tositumomab played a major role in establishing these therapy classes, but it's also useful to contrast radioimmunoconjugates with other radiopharmaceuticals, such as iodine-131 therapies, which a lot of places do at this time, used for thyroid diseases, or radium 223, used for metastatic prostate cancer. Unlike those agents, radioimmunoconjugates rely on antibody-mediated targeted rather than physiologic uptake or bone affinity." TS 4:55 "I just try to explain to [patients] that radiation exposure is like being next to a flame. The further you are away, the less heat you get, the less exposure you get. These patients can be radioactive for three days, seven days—it just depends on how fast they excrete it through their bodies with half-life exposure." TS 9:33 "While only one agent is currently approved, the principles established by radioimmunoconjugates continue to guide development for newer targeted radiopharmaceuticals. Emerging agents aim to improve targeting, reduce toxicity, and expand indications beyond hematologic malignancies. This evolution underscores the importance of nursing education in this rapidly changing field." TS 10:41 "Radioimmunoconjugates represent an important bridge between traditional oncology treatments and the future of targeted therapies. Oncology nurses play a vital role in ensuring safe delivery, patient understanding, and collaboration between multidisciplinary teams. So, it's very important to educate and also stay up to date on evidence-based practices." TS 13:12
In this episode of Ageless Future, Cade Archibald reframes aging as a bioenergetic problem—not simply “wear and tear” or the passage of time. He explains how mitochondrial dysfunction can quietly precede chronic disease through declining ATP production, rising oxidative stress (ROS), and increasingly inefficient cellular signaling, setting the stage for issues like neurodegeneration, cardiometabolic disease, and autoimmune/inflammatory disorders. Cade highlights how mitochondria act as intelligent signaling hubs that help the body adapt to stress, why symptoms often appear before labs look abnormal, and how restoring energy can unlock repair, detoxification, hormone balance, and immune stability. He closes with practical “mitochondria-charging” strategies—recovery, sleep, heat/cold exposure, red light, and foundational habits—challenging listeners to prioritize restoration to restore health.AGELESS FUTURE:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
In this podcast episode, the speaker shares his personal journey of quitting THC, explaining his reasons, the gradual process over several years, and the impacts on his life. He recounts his history with THC, from early recreational use to daily dependence for sleep aid during medical school and residency. The speaker emphasizes that he does not oppose cannabis, recognizing its medicinal value, but wanted to overcome his dependency. He details his method of reducing THC use through vaping and CBD alternatives, ultimately leading to his last use in January 2025. Alongside his personal story, he discusses the benefits and potential negative impacts of THC and other cannabinoids, offering insights into who might consider quitting and why. Cannabis, THC & Quitting Cannabis (Marijuana) — NIDA overview: https://nida.nih.gov/research-topics/cannabis-marijuana Cannabis Use Disorder — NCBI Bookshelf (StatPearls): https://www.ncbi.nlm.nih.gov/books/NBK538131/ Sleep, REM & Withdrawal Cannabis and sleep architecture — systematic review (PubMed): https://pubmed.ncbi.nlm.nih.gov/40967124/ Effects of cannabinoids on sleep — review (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC8116407/ Non-Intoxicating Cannabinoids Mentioned CBD + anxiety — systematic review (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC11595441/ CBG — acute effects + cognition (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC11246434/ THCV — overview/commentary (PubMed): https://pubmed.ncbi.nlm.nih.gov/33526143/ CBC — therapeutic potential review (PMC): https://pmc.ncbi.nlm.nih.gov/articles/PMC11493452/ Potency: Concentrates Marijuana Concentrates — NIDA DrugFacts PDF: https://nida.nih.gov/sites/default/files/df-marijuana-concentrates.pdf Supplements Mentioned Omega-3 Fatty Acids — NIH ODS (Consumer): https://ods.od.nih.gov/factsheets/Omega3FattyAcids-Consumer/ Vitamin D — NIH ODS (Consumer): https://ods.od.nih.gov/factsheets/VitaminD-Consumer/ Show Notes 00:00 Introduction: Why I Quit THC 02:18 My History with THC 06:10 Transition to Medical Use 13:53 The Quitting Process 20:11 Benefits and Challenges of Quitting 25:07 Thoughts on THC and Other Cannabinoids 33:25 Conclusion and Final Thoughts The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
Credits: 0.25 AMA PRA Category 1 Credit™ CME/CE Information and Claim Credit: https://www.pri-med.com/online-education/podcast/frankly-speaking-cme-469 Overview: Tune in to hear how self-collected vaginal human papillomavirus (HPV) testing has potential to expand access to cervical cancer screening and reduce barriers for your patients. This episode reviews cervical cancer screening guidelines, follow-up recommendations, and how to consider offering self-collection as an option to increase screening rates and improve preventive care in your practice. Episode resource links: CA CancerJClin.2026;e70041. DOI:10.3322/caac.70041 US Food and Drug Administration (FDA). Device Classification Under Section 513(f)(2)(De Novo). Device for home collection and transport of vaginal specimens by lay users for use in an approved HPV molecular assay. FDA; 2025. FranklySpeaking@pri-med.com The views expressed in this podcast are those of Dr. Domino and his guests and do not necessarily reflect the views of Pri-Med.
In this episode of the Ageless Future Podcast, host Cade Archibald sits down with Derek Norsworthy, CEO of NeuroCatch, to explore a breakthrough approach to cognitive assessment using objective “brain vital signs.” Derek shares how NeuroCatch evolved from decades of neuroscience research into a point-of-care tool designed to measure cognitive function with lab-level sensitivity—helping clinicians move beyond subjective questionnaires and “you seem fine” evaluations. Together, they discuss how NeuroCatch is used to establish baseline brain performance, track improvements from longevity and brain-optimization protocols (including peptides, stem cells, HBOT, red light, and other interventions), and detect subclinical cognitive changes that may not appear on MRI/CT or standard assessments. Derek also recounts his personal health journey from burnout and hormone disruption to functional medicine recovery, reinforcing the episode's theme: better outcomes happen when innovative technology and integrative care meet in the middle. Derek Norsworthy: I began my career as a clinical professional and evolved into a recognized leader in healthcare technology, specializing in the integration of electronic health record systems and innovation across large U.S. health systems. Through roles as a strategic advisor, business consultant, and healthcare entrepreneur, I've guided organizations in adopting advanced technologies to improve clinical workflows, operations, and patient outcomes. Now serving as CEO of HealthtechConnex, I bring my clinical experience and passion for innovation full circle to help bring cutting-edge health technologies to market. Beyond healthcare, I'm a husband, father, endurance athlete, leadership coach, and technology entrepreneur, driven by a mission to inspire others with the tools, mindset, and confidence to live life fully.LIKE/FOLLOW/SUBSCRIBE DEREK:LinkedIn: https://www.linkedin.com/in/derek-norsworthy-88427530b/LIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/AGELESS FUTURE RESOURCES:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldDISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Most people think they go into your body and make all new tissue… but in actuality, they are a delivery mechanism of growth factors. I call them the ultimate traffic cop. In this episode, the host converses with Dr. Jesse Morse, a physician specializing in regenerative and anti-aging medicine. They delve into the intricacies of stem cells and their various sources, including bone marrow, fat, and donor tissue. Dr. Morse highlights the role of exosomes and growth factors in the healing process. The discussion also focuses on the prevention and treatment of Achilles tendon tears, emphasizing the importance of blood supply, proper diagnosis, and innovative therapies. Additionally, they explore the benefits and applications of various peptides, including BPC 157, TB 500, and MotC, for enhancing healing, anti-aging, and overall health. Dr. Morse also addresses the significance of nutrition and detoxification in maintaining optimal health and preventing injuries. Dr. Jesse Morse is a Miami-based, double board-certified physician in Family and Sports Medicine who specializes in regenerative medicine, injury recovery, and longevity. Since shifting from traditional sports medicine in 2020, he has focused on non-surgical approaches to tendon and ligament injuries using therapies like PRP, stem-cell–based treatments, exosomes, and peptides, alongside functional and anti-aging strategies centered on mitochondrial health, immune support, toxin reduction, and personalized recovery—helping everyone from active adults to high-performance athletes restore function and prevent major injuries like Achilles tears while educating widely online. Connect with him on: Instagram: https://www.instagram.com/drjessemorse/ — Sports medicine, regenerative medicine & insights Linktree (aggregated links to socials & resources): https://linktr.ee/DrJesseMorse Supplements, Compounds & Peptides Collagen (protein / connective tissue support): https://www.ncbi.nlm.nih.gov/books/NBK507922/ Vitamin C (collagen activation / antioxidant): https://ods.od.nih.gov/factsheets/VitaminC-HealthProfessional/ Creatine (muscle & mitochondrial support): https://ods.od.nih.gov/factsheets/Creatine-HealthProfessional/ BPC-157 (peptide – tendon & gut healing): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504390/ TB-500 / Thymosin Beta-4 (peptide – tissue repair): https://pubmed.ncbi.nlm.nih.gov/22674782/ GHK-Cu (copper peptide – skin, joints, stem-cell signaling): https://pubchem.ncbi.nlm.nih.gov/compound/GHK-Cu MOTS-c (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/25174616/ SS-31 / Elamipretide (mitochondrial peptide): https://pubmed.ncbi.nlm.nih.gov/29515116/ Thymosin Alpha-1 (immune modulation peptide): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8367996/ LL-37 (antimicrobial / immune peptide): https://pubmed.ncbi.nlm.nih.gov/15184378/ 5-Amino-1MQ (NNMT inhibitor / fat loss): https://pubchem.ncbi.nlm.nih.gov/compound/5-Amino-1MQ N-Acetylcysteine (NAC – liver & detox support): https://www.ncbi.nlm.nih.gov/books/NBK537183/ Glutathione (antioxidant / detox): https://ods.od.nih.gov/factsheets/Glutathione-HealthProfessional/ NAD⁺ / NMN / NR (mitochondrial & anti-aging support): NMN: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-mononucleotide NR: https://pubchem.ncbi.nlm.nih.gov/compound/Nicotinamide-riboside Regenerative & Injection Therapies PRP – Platelet-Rich Plasma: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6990861/ Bone Marrow–Derived Stem Cells (BMAC): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4630382/ Adipose-Derived Stem Cells: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6416130/ Amniotic / Placental Tissue Products: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8124018/ Exosomes (cell signaling vesicles): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8465611/ Ultrasound-Guided Injections: https://radiopaedia.org/articles/musculoskeletal-ultrasound-guided-injection Needle Tenotomy (scar-tissue disruption): https://pubmed.ncbi.nlm.nih.gov/30428129/ Detox, Blood & Environmental Interventions Sauna (heat detox & cardiovascular benefit): https://www.health.harvard.edu/staying-healthy/saunas-and-your-health Binders – Modified Citrus Pectin: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5452227/ GI Detox / Toxin Binders (general concept): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3654245/ Heavy Metal Chelation (DMPS concept): https://pubmed.ncbi.nlm.nih.gov/12198644/ Mercury Toxicity: https://www.cdc.gov/mercury/index.html Microplastics in Humans: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7068600/ EBOO Therapy (ozone-based blood filtration): https://pubmed.ncbi.nlm.nih.gov/36681461/ Therapeutic Plasma Exchange (TPE): https://www.ncbi.nlm.nih.gov/books/NBK557561/ INUSpheresis (advanced plasma filtration): https://pubmed.ncbi.nlm.nih.gov/37324197/ Medications & Drug Classes Mentioned Corticosteroids (Prednisone – tendon risk): https://medlineplus.gov/druginfo/meds/a601102.html Fluoroquinolone Antibiotics (tendon rupture risk): https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-fluoroquinolone-antibiotics GLP-1 Agonists (Semaglutide / Tirzepatide / Retatrutide discussion): Semaglutide: https://pubmed.ncbi.nlm.nih.gov/36421543/ Tirzepatide: https://pubmed.ncbi.nlm.nih.gov/35220624/ Nutrition & Food-Related Mentions Protein Intake & Muscle Health: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6566799/ American Gluten vs European Wheat: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799814/ Seed Oils & Inflammation (discussion topic): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6196963/ Dairy & Inflammation (contextual mention): https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5122229/ Key Mechanisms & Concepts Poor Blood Supply in Achilles Tendon (Watershed Zone): https://pubmed.ncbi.nlm.nih.gov/17021202/ Mitochondrial Dysfunction & Aging: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4843959/ Stem Cells as "Medicinal Signaling Cells": https://pubmed.ncbi.nlm.nih.gov/25784997/ Show Notes 00:00 Introduction to Exosomes and Stem Cells 01:01 Dr. Morse's Background and Transition to Regenerative Medicine 02:03 Achilles Tendon Tears: Causes and Prevention 05:02 Preventative Measures and Treatments for Achilles Injuries 10:26 The Role of Nutrition in Tendon Health 12:53 Peptides and Their Impact on Tendon Health 15:50 Stem Cells: Misconceptions and Applications 20:52 Comparing Stem Cell Sources and Their Potency 29:52 The Controversy of International Stem Cell Treatments 34:04 Cleaning Toxins from Your Blood 34:19 The Toxic Burden in Our Environment 35:57 Practical Detox Methods 37:47 Mercury and Heavy Metal Testing 44:47 The Problem with American Gluten 46:49 Underrated Peptides for Health 53:42 Growth Hormone and Anti-Aging 01:03:34 Advanced Blood Cleaning Techniques 01:04:51 Conclusion and Contact Information The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode of the Ageless Future Podcast, host Cade Archibald reframes aging as a modular, systems-based process rather than a simple function of time. Drawing on the Hallmarks of Aging and the geroscience framework, Cade explores how different biological systems—immune function, mitochondrial health, stem cell signaling, cellular senescence, vascular elasticity, brain plasticity, and nutrient sensing—decline at different rates and influence one another. He explains how chronic inflammation acts as a unifying driver of dysfunction and highlights practical strategies to target specific aging bottlenecks, including nutrition, exercise, mitochondrial optimization, peptides, detoxification, and metabolic support. The core message: aging is not inevitable or uniform—it's engineerable. By focusing on system repair instead of surface-level anti-aging, we can enhance resilience, cognitive function, recovery, and long-term vitality.AGELESS FUTURE:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprintSign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registrationBooks: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibaldArticles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.FutureLinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. Cade Archibald is COO and Co-Founder of Ageless Future, also not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a dynamic phase shaping the industry, marked by scientific advancements, regulatory changes, and strategic shifts within major companies.Teva Pharmaceuticals is making significant strides under the leadership of CEO Richard Francis. The company is transitioning from its traditional focus on generic drugs to a more innovative biopharmaceutical approach. This strategic pivot aims to position Teva alongside industry giants in the biopharma sector, highlighting the increasing importance of innovation over generics in today's competitive landscape.Similarly, Fujifilm is enhancing its competitive edge by capitalizing on its biologics capacity. Rather than pursuing large mergers and acquisitions, Fujifilm is focusing on internal growth, underscoring a broader industry trend where companies are investing in organic growth and technological enhancements to maintain their market positions. This shift reflects a growing recognition of the value of leveraging unique facility designs and capabilities to boost production and efficiency.In regulatory news, the U.S. Food and Drug Administration (FDA) has mandated that pharmaceutical companies like Sanofi, GSK, AstraZeneca, and CSL include warnings about febrile seizures on flu vaccine labels. While these seizures are typically brief and harmless, transparent communication is crucial to maintain patient trust in vaccination programs. This regulatory update exemplifies the FDA's proactive efforts to enhance drug safety communications and address potential adverse effects associated with vaccines.The FDA has also issued untitled letters to Beone and ImmunityBio for promotional materials that potentially violated advertising guidelines. This action underscores the agency's vigilance in ensuring pharmaceutical marketing practices meet required standards of accuracy and transparency.Meanwhile, former Emergent BioSolutions CEO Robert Kramer faces insider trading allegations related to the sale of company shares before public disclosure of contamination issues at a production facility. This legal action brings to light ongoing scrutiny within the industry regarding corporate governance and ethical practices.In terms of advertising spending, AbbVie's Skyrizi topped annual TV ad spending charts for pharmaceuticals, closely followed by J&J's Tremfya. This highlights the continued emphasis on direct-to-consumer advertising as companies compete for market share in therapeutic areas.Internationally, companies like AbbVie are making strategic moves into emerging therapeutic spaces such as bispecific antibodies. AbbVie's recent deal to enter the PD-1xVEGF bispecific space signifies a growing interest in novel therapeutic modalities that offer potential breakthroughs in cancer treatment.At the policy level, former President Donald Trump announced "The Great Healthcare Plan," targeting insurance industry reforms and drug pricing. Although specifics remain sparse, this initiative reflects ongoing political discourse around healthcare affordability—a critical issue shaping industry strategies and public expectations.Turning our attention to Vedanta Biosciences, the company is reallocating resources toward its lead live bacteria cocktail program by significantly reducing its workforce. This move highlights growing interest in microbiome-based therapies as a novel approach to treating diseases by modulating gut microbiota. Vedanta's focus could have substantial implications for future therapeutic options, particularly in immune-related conditions.At the J.P. Morgan Healthcare Conference (JPM26), Chugai Pharmaceutical emphasized enhancing its recognition in the U.S. biopharma sector through new scientific avenues. This strategy underscores the importance of innovation and collaboration for Support the show
Most "detox" advice focuses on cleanses and quick fixes — but real detoxification is a constant, biological process your body runs every day. In this solo episode, the host breaks down how detoxification actually works, starting with what counts as a "toxin" (including hormones and environmental chemicals) and how the body packages them for elimination. You'll learn the key roles of the liver, kidneys, and gut — and why detox can succeed in the liver but fail in the intestines, especially when certain gut bacteria produce enzymes like β-glucuronidase that can send toxins back into circulation. The episode covers major detox pathways (including glucuronidation), the importance of bile flow and regular bowel movements, and why fiber is one of the biggest levers you can pull to support elimination. It also explores how hydration, electrolyte balance, stress, and overtraining can influence detox capacity, plus the limited-but-real role sweating may play in clearing certain heavy metals. Finally, you'll get practical strategies for supporting a healthier gut microbiome and reducing toxin buildup — from diet and polyphenols to commonly discussed supplements like NAC, glycine, and taurine. Supplements & Compounds Magnesium (supplement/mineral): https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/ Zinc (supplement/mineral): https://ods.od.nih.gov/factsheets/Zinc-HealthProfessional/ Psyllium (fiber / bulk-forming laxative): https://medlineplus.gov/druginfo/meds/a601104.html Spirulina (supplement / "blue-green algae"): https://www.ncbi.nlm.nih.gov/books/NBK548312/ Activated Charcoal (binder / poisoning use): https://pmc.ncbi.nlm.nih.gov/articles/PMC6620762/ Glycine (amino acid): https://pubchem.ncbi.nlm.nih.gov/compound/Glycine N-Acetylcysteine (NAC): https://www.ncbi.nlm.nih.gov/books/NBK537183/ Foods / Gut & Microbiome Mentions Fermented foods (kimchi, sauerkraut, etc.): https://health.clevelandclinic.org/5-reasons-you-should-add-more-fermented-foods-to-your-diet-infographic Kimchi (specific fermented food mentioned): https://health.clevelandclinic.org/is-kimchi-good-for-you Sourdough (food example mentioned): https://en.wikipedia.org/wiki/Sourdough Berries (food example mentioned): https://en.wikipedia.org/wiki/Berry Wild rice (food example mentioned): https://en.wikipedia.org/wiki/Wild_rice Medications Mentioned Ibuprofen (Advil): https://medlineplus.gov/druginfo/meds/a682159.html Naproxen (NSAID): https://medlineplus.gov/druginfo/meds/a681029.html Lifestyle / Modalities Mentioned Sauna: https://www.health.harvard.edu/staying-healthy/saunas-and-your-health Infrared sauna: https://health.clevelandclinic.org/infrared-sauna-benefits Red light therapy (photobiomodulation): https://my.clevelandclinic.org/health/articles/22114-red-light-therapy Environmental / Exposure Topics Mentioned BPA (bisphenol A): https://www.niehs.nih.gov/health/topics/agents/sya-bpa Phthalates: https://wwwn.cdc.gov/tsp/substances/ToxChemicalListing.aspx?toxid=41 Lead exposure: https://www.cdc.gov/lead-prevention/prevention/index.html Arsenic in rice: https://www.fda.gov/food/environmental-contaminants-food/what-you-can-do-limit-exposure-arsenic Key Mechanism/Concept Mentioned Gut microbial β-glucuronidase (and "glucuronidation" talk): https://pmc.ncbi.nlm.nih.gov/articles/PMC9717552/ Show Notes 00:00 Introduction to Detoxification 02:00 Understanding Toxins and Hormones 05:36 Common Environmental Toxins 07:10 The Detoxification Process 10:52 Gut Health and Detoxification 20:07 Sweating and Detoxification 23:35 Supplements for Detoxification 29:31 Conclusion and Final Tips The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this kickoff episode of Creating an Ageless Future, host Regan Archibald opens the new year by reflecting on recent personal highlights, upcoming program updates (including a new weekly Wednesday time), and a simple theme for 2026: get clearer results by removing what no longer serves you. He explores how “over-optimization” can create decision fatigue, why the easiest habits are the ones that stick, and how small environment tweaks can make good choices more automatic. Regan also walks through his three-part view of health—lifestyle, energy for enjoyable activities, and fun experiences—and introduces a practical self-audit framework (EPIC) to help listeners identify common obstacles and set a focused, doable next step for the year ahead.RESOURCES: AGELESS FUTURE:Book Comprehensive Labs: https://agelessfuture.com/longevity-labs/FREE copy of The Peptide Blueprint: https://agelessfuture.com/blueprint Sign up for future Health Accelerator Challenges calls LIVE! https://us02web.zoom.us/webinar/register/WN_YZsiUMOzSyqcE8IinC5YEQ#/registration *Books: https://www.amazon.com/Books-Regan-Archibald/s?rh=n%3A283155%2Cp_27%3ARegan%2BArchibald * Articles: https://medium.com/search?q=Regan+ArchibaldLIKE/FOLLOW/SUBSCRIBE AGELESS FUTURE:YouTube -https://www.youtube.com/@ReganArchibald / https://www.youtube.com/@Ageless.Future LinkedIn: https://www.linkedin.com/in/regan-archibald-ab70b813Instagram: https://www.instagram.com/ageless.future/Facebook: https://www.facebook.com/AgelessFutureHealth/DISCLAIMER: This video is for educational purposes only and does not provide medical advice, diagnosis, or treatment. Many of the molecules discussed in this video are research compounds and are not approved by the U.S. Food and Drug Administration (FDA) for any specific medical use, indication, or condition. They are mentioned only in the context of existing scientific literature and ongoing research and are not being recommended, prescribed, sold, or offered through this video. This content does not endorse or recommend any specific tests, products, procedures, or treatment protocols.References to our clinic are for general educational context only; investigational or non‑approved products are not available for direct ordering or prescribing based solely on viewing this content. Do not start, stop, or change any medication, peptide, or supplement based on this video. All medical decisions must be made with a licensed prescribing clinician after a proper evaluation. No provider–patient relationship is created by viewing this content or contacting our clinic. Regan Archibald is a Licensed Acupuncturist and longevity coach. He is not a medical doctor. All medical decisions, lab ordering, and prescribing in our clinic are performed only by our licensed medical team (MD, APRN, PA). Viewers should follow the guidance of their own licensed clinicians and local health authorities regarding diagnosis and treatment decisions.
Morrison Foerster partners Kate Driscoll and Nate Mendell, both former federal prosecutors and members of the firm's Investigations + White Collar Defense Group, hosted the twelfth episode of When Your Life Sciences Are on the Line, where leading practitioners and thought leaders share the insights and advice needed to manage business and legal risk in the life sciences sector. In this episode, Kate and Nate speak with Brigid Bondoc, partner and leader of Morrison Foerster's U.S. Food and Drug Administration (FDA) & Healthcare Regulatory and Compliance Group. Together, they discuss the evolving role of artificial intelligence (AI) within the FDA and its implications for the life sciences industry. They address how the FDA is beginning to integrate AI tools like “Elsa” to improve efficiency in inspections, data analysis, and safety monitoring. Brigid also explores key regulatory and compliance challenges surrounding AI-driven clinical decision support software, emphasizing the importance of explainability and human oversight. The conversation closes with an examination of the FDA's new approach to releasing complete response letters, and how this increased transparency may reshape industry strategies for engagement with the agency.
Mifepristone used with misoprostol is the most common abortion regimen in the US. It is also a focal point of reproductive health policy and politics, with controversy over its legal status and regulation by the US Food and Drug Administration (FDA). Author G. Caleb Alexander, MD, MS, from Johns Hopkins discusses this and more with JAMA Deputy Editor Joseph S. Ross, MD, MHS. Related Content: The US Food and Drug Administration's Regulation of Mifepristone Politics, Science, and the Future of FDA Drug Regulation
What if your "healthy" water intake is still quietly hurting your performance? In this solo episode, Dr. Mike breaks down hydration from a performance-first perspective — how dehydration affects cognition and physical output, why "8 glasses a day" is an oversimplified myth, and how to personalize your intake based on body size, activity level, diet, environment, and medications. He walks through practical guidelines (including 30–35 ml/kg/day), how to use urine + thirst cues without overcomplicating it, and why timing matters (especially around workouts, sauna use, and sleep). A major focus of this episode is electrolytes — what they do, how sweat changes your needs, and why sodium is often the key limiter for athletes, sauna users, and people eating low-carb/keto. Dr. Mike also covers potassium and magnesium, caffeine and hydration, the risks of overhydration, and the classic warning signs of hyponatremia. This is a comprehensive, no-BS guide to staying hydrated, replenishing electrolytes correctly, and improving energy, performance, and sleep. Resources: Electrolyte & Hydration Products LMNT Official Home Page: https://drinklmnt.com/ LMNT Recharge Electrolyte Drink Mix: https://drinklmnt.com/products/lmnt-recharge-electrolyte-drink LMNT Variety Pack: https://drinklmnt.com/products/lmnt-recharge-variety-pack DIY Homemade Electrolyte Drink (LMNT Science): https://science.drinklmnt.com/electrolytes/best-homemade-electrolyte-drink-for-dehydration Gatorade Electrolyte Powder for Hydration (Official): https://www.gatorade.com/powders Medical / Health Conditions & Guidance Hyponatremia — Symptoms & Causes (Mayo Clinic): https://www.mayoclinic.org/diseases-conditions/hyponatremia/symptoms-causes/syc-20373711 Hyponatremia — Diagnosis & Treatment (Mayo Clinic): https://www.mayoclinic.org/diseases-conditions/hyponatremia/diagnosis-treatment/drc-20373715 Lab Tests Magnesium, RBC (Labcorp): https://www.labcorp.com/tests/080283/magnesium-rbc Mineral / Supplement References Magnesium — Fact Sheet for Health Professionals (NIH ODS): https://ods.od.nih.gov/factsheets/Magnesium-HealthProfessional/ Potassium — Fact Sheet for Health Professionals (NIH ODS): https://ods.od.nih.gov/factsheets/Potassium-HealthProfessional/ Dietary Supplements for Exercise and Athletic Performance — Fact Sheet for Health Professionals (NIH ODS): https://ods.od.nih.gov/factsheets/ExerciseAndAthleticPerformance-HealthProfessional/ People / Sources Mentioned Robb Wolf (LMNT Science author page): https://science.drinklmnt.com/authors/robb-wolf Robb Wolf (official site): https://robbwolf.com/ Huberman Lab (official site): https://www.hubermanlab.com Show Notes 00:00 Welcome Back to the Hart2Heart Podcast! 00:55 The Importance of Hydration 01:46 Daily Water Intake Guidelines 04:16 Sweat and Electrolyte Loss 06:56 Sodium: The Key Electrolyte 12:22 Potassium: Essential for Muscle and Heart Health 15:20 Magnesium: The Multi-Functional Mineral 20:08 Other Important Nutrients 22:33 Hydration Strategies and Special Populations 26:37 Final Tips and Conclusion The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight, and de-prescribing pharmaceuticals — using medications only when absolutely necessary. Beyond health science, we explore the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this podcast is for you.We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect with Dr. Mike Hart Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of significant events that are shaping the landscape of this dynamic industry. The ever-evolving arena of drug approvals, regulatory challenges, and strategic shifts continues to captivate stakeholders across the globe.Sanofi's recent acquisition of Dynavax for $2.2 billion illustrates a prevailing trend within the sector—mergers and acquisitions aimed at expanding vaccine portfolios in response to global health priorities. This strategic move provides Sanofi with access to Heplisav-B, a hepatitis B vaccine, thereby reinforcing the importance of broadening vaccine offerings amid ongoing global health concerns.The U.S. Food and Drug Administration (FDA) has been active in granting approvals for new therapies, reflecting ongoing efforts to address a wide range of medical needs. Agios Pharmaceuticals has received approval for Aqvesme, a treatment designed specifically for anemia in patients with either alpha- or beta-thalassemia. Meanwhile, Vanda Pharmaceuticals has secured approval for Nereus, a novel motion sickness treatment. These approvals highlight the FDA's dedication to advancing treatments for both common and rare medical conditions.A noteworthy milestone was achieved by Omeros Corporation as it secured FDA approval for Yartemlea—its first U.S. approval in 31 years. This drug is a novel treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy, underscoring the industry's focus on developing therapies for niche yet critical medical conditions.Verastem Oncology has opted to halt its phase 1/2 trial of a KRAS G12C inhibitor targeting non-small cell lung cancer due to increasing competition from next-generation inhibitors. This decision reflects the competitive and rapidly evolving landscape of oncology therapeutics where companies must adapt their strategies based on interim data and market dynamics.Foresee Pharmaceuticals has reported promising phase 3 results for Camcevi in treating central precocious puberty (CPP), a rare hormonal disorder. This demonstrates the potential for repurposing established drugs to address unmet needs in pediatric endocrinology.Inflarx is actively exploring partnerships to revitalize its C5a antibody vilobelimab which was initially developed for pyoderma gangrenosum but faced setbacks after a terminated phase 3 trial. The company's persistence in seeking new pathways forward exemplifies the challenges and resilience required in drug development, especially for rare diseases.Regulatory hurdles remain a significant challenge as illustrated by Outlook Therapeutics' ophthalmic bevacizumab facing another FDA rejection. Such outcomes emphasize the stringent regulatory environment that companies must navigate to bring innovative therapies to market.A federal judge's temporary pause on the 340B rebate pilot underscores ongoing legal and regulatory debates impacting healthcare policy and industry operations. The contentious rollout of this pilot reflects broader tensions between administrative actions and healthcare stakeholders.As we look forward, industry analysts anticipate that the surge in mergers and acquisitions observed in late 2025 will persist into 2026. Companies are driven by growth aspirations through strategic acquisitions aimed at expanding their pipelines and market reach.Despite positive advancements, some companies face setbacks. Johnson & Johnson's discontinuation of its $1.2 billion eczema therapy due to unsatisfactory clinical results highlights the inherent risks and unpredictability of drug development. Similarly, Genmab's withdrawal of a cancer drug from development underscores these challenges within oncology research.In contrast, Neuralink's plans to ramp up production of its brain-computer interface devices highliSupport the show
Fluoridated water has shaped U.S. dental policy since the 1940s, when officials began adding fluoride to public water supplies in an effort to reduce childhood cavities.1 As of 2022, the U.S. Centers for Disease Control and Prevention (CDC) reported that 72.3% of Americans on community water systems (about 62.8% of the entire population) received fluoridated water,2 making systemic exposure nearly unavoidable. Mounting evidence now shows that fluoride offers little measurable benefit for dental health while introducing significant risks, particularly for children. Many countries, including Germany, Sweden, and the Netherlands, have already abandoned water fluoridation.3 In the U.S., Utah and Florida recently became the first states to ban the practice, and similar bills are emerging elsewhere.4 However, in places where fluoride is not added to tap water, fluoride supplements are prescribed for infants and children. Recently, the U.S. Food and Drug Administration (FDA) announced it is taking action to restrict the use of these prescription fluoride supplements, following a directive from the Make America Healthy Again (MAHA) Commission to reassess their safety and effectiveness.5
Frank Yiannas, M.P.H. is a renowned food safety leader and executive, food system futurist, author, professor, past president of the International Association of Food Protection (IAFP), and advocate for consumers. Most recently, he served under two different administrations as the Deputy Commissioner for Food Policy and Response at the U.S. Food and Drug Administration (FDA), a position he held from 2018–2023, after spending 30 years in leadership roles with Walmart and the Walt Disney Company. After retiring from FDA, Mr. Yiannas founded Smarter FY Solutions to help organizations address critical food safety and supply chain challenges. He also advises several well-known companies, offering consultancy services to modernize compliance strategies and ensure that clients meet regulatory requirements and industry standards. Throughout his career, Mr. Yiannas has been recognized for his role in strengthening food safety standards in new and innovative ways, as well as building effective food safety management systems based on modern, science-based, and tech-enabled prevention principles. Drew McDonald is the Senior Vice President of Quality and Food Safety at Taylor Fresh Foods in Salinas, California, where he oversees the quality and food safety programs across the foodservice, retail, and deli operations under both FDA and U.S. Department of Agriculture (USDA) jurisdictions. Mr. McDonald works with an impressive team developing and managing appropriate and practical quality and food safety programs for fresh food and produce products. He has more than 30 years of experience in fresh produce and fresh foods. Over the course of his career, Mr. McDonald has worked with growers and processors of fresh food and produce items across the globe. He currently serves on numerous food safety-related technical committees and has participated in the authorship of many produce safety articles and guidelines. He serves on the Food Safety Summit Educational Advisory Board and is a former chair of the Center for Produce Food Safety's Technical Committee and United Fresh's Technical Council. Mr. McDonald received his education from Lawrence University in Wisconsin. John Besser, Ph.D. worked for ten years as Deputy Chief of the Enteric Diseases Laboratory Branch at the U.S. Centers for Disease Control and Prevention (CDC), where he was involved in national and global programs to detect, characterize, and track gastrointestinal diseases. Prior to CDC, Dr. Besser led the infectious disease laboratory at the Minnesota Department of Health (MDH) for 19 years and served as a clinical microbiologist at the University of Minnesota Hospital for five years. He currently works as an independent contractor and consultant. Dr. Besser is the author or co-author of more than 70 publications. He received his Ph.D. and M.S. degree from the University of Minnesota. Craig Hedberg, Ph.D. is a Professor in the Division of Environmental Health Sciences at the University of Minnesota and Co-Director of the Minnesota Integrated Food Safety Center of Excellence. He promotes public health surveillance as a prerequisite for effective food control, and his work focuses on improving methods for collaboration among public health and regulatory agencies, academic researchers, and industry to improve foodborne illness surveillance and outbreak investigations. With a background in public health practice, Dr. Hedberg also focuses on public health workforce development and works with state, local, and tribal public health partners to build capacity for preparedness and emergency response. He is a member of the Council of State and Territorial Epidemiologists, the Minnesota Environmental Health Association, and IAFP. Dr. Hedberg holds a Ph.D. in Epidemiology and an M.S. degree in Environmental Health, both from the University of Minnesota. In this episode of Food Safety Matters, we speak with Mr. Yiannas, Mr. McDonald, Dr. Besser, and Dr. Hedberg [6:43] about: The increasing rate of food recalls issued by federal regulatory agencies, and what that might imply about the current systems for outbreak investigation and disease surveillance How federal and state public health agencies conduct foodborne illness outbreak investigations and the current success rates of these investigations Elements of the foodborne illness outbreak investigation process that are working well Potential areas for improvement for foodborne illness outbreak investigations and the metrics for "success" An idea for a National Foodborne Outbreak Investigation Board, similar to the model used for airlines with the National Transportation Safety Board, and how such a system might help improve food safety in the U.S. Sponsored by: Michigan State University Online Food Safety Program We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
"They [monoclonal antibodies] are able to cause tumor cell death by binding to and blocking to necessary growth factor signaling pathways for tumor cell survival. That's going to be dependent on the target of the antibody, but I'll give an example of epidermal growth factor, or EGFR. This is overexpressed in several different kinds of cancers where activation of this growth factor increases the amount of proliferation and migration of cancer cells. So, if we bind to it and block to it, then that would help halt these pathways and stop cancer cell growth," Carissa Ganihong, PharmD, BCOP, oncology and bone marrow transplantation clinical pharmacist at Hackensack University Medical Center in New Jersey, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about monoclonal antibodies. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.75 contact hours of nursing continuing professional development (NCPD) (including 45 minutes of pharmacotherapeutic content) by listening to the full recording and completing an evaluation at courses.ons.org by December 26, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge in the history of, the mechanism of action of, and the use of monoclonal antibodies in the treatment of cancer. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 391: Pharmacology 101: Antibody–Drug Conjugates Episode 383: Pharmacology 101: Bispecific Antibodies Episode 375: Pharmacology 101: VEGF Inhibitors Episode 338: High-Volume Subcutaneous Injections: The Oncology Nurse's Role Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction Episode 275: Bispecific Monoclonal Antibodies in Hematologic Cancers and Solid Tumors ONS Voice articles: An Oncology Nursing Overview of Biosimilars Make Subcutaneous Administration More Comfortable for Your Patients Oncology Nurses' Role in Translating Biomarker Testing Results Reduce Chair Time by as Much as 16 Minutes by Priming IVs With Drug Shorter Administration Times Still Require High-Acuity Care The Names of Targeted Therapies Give Clues to How They Work ONS Voice drug reference sheets: Datopotamab deruxtecan-dlnk Enfortumab vedotin Margetuximab-cmkb Mirvetuximab soravtansine-gynx Nivolumab and hyaluronidase-nvhy Nivolumab and relatlimab-rmbw Pembrolizumab and berahyaluronidase alfa-pmph Retifanlimab-dlwr ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Bolusing IV Administration Sets With Monoclonal Antibodies Reduces Cost and Chair Time: A Randomized Controlled Trial Management of Immunotherapy Infusion Reactions Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Safety and Adverse Event Management of VEGFR-TKIs in Patients With Metastatic Renal Cell Carcinoma Oncology Nursing Forum articles: Administration of Subcutaneous Monoclonal Antibodies in Patients With Cancer Depressive Symptoms and Quality of Life Associated With the Use of Monoclonal Antibodies in Breast Cancer Treatment ONS huddle cards: Bispecifics Checkpoint Inhibitors Monoclonal Antibodies Other ONS resources: Biomarker Database Bispecific Antibodies video Patient Education Sheets Antibodies article: A Comprehensive Review About the Use of Monoclonal Antibodies in Cancer Therapy Cureus article: A Comprehensive Review of Monoclonal Antibodies in Modern Medicine: Tracing the Evolution of a Revolutionary Therapeutic Approach Association of Cancer Care Centers (ACCC) homepage Cancer Immunology, Immunotherapy article: Therapeutic Antibodies in Oncology: An Immunopharmacological Overview Drugs@FDA package inserts Future Oncology article: Biosimilars: What the Oncologist Should Know Hematology/Oncology Pharmacy Association homepage National Comprehensive Cancer Network homepage Network for Collaborative Oncology Development and Advancement (NCODA) subcutaneous therapy article Oncolink: Side Effects of Immunotherapy World Health Organization: New International Nonproprietary Names (INN) Monoclonal Antibody Nomenclature Scheme To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org. Highlights From This Episode "Prior to monoclonal antibodies, all we really had were these toxic chemotherapies or toxic radiation, so it was recognized how great it would be if we could have a treatment that was much more specific to the tumor cells and have agents that have less toxicities. These advancements in monoclonal antibody production began in the 1980s. ... Eventually, we had the first monoclonal antibody that was approved by the U.S. Food and Drug Administration (FDA) for an oncologic indication, rituximab." TS 4:14 "Nowadays, we do have treatments that are also considered tumor-agnostic. This is when a patient has a certain biomarker, then that treatment can be given and FDA approval was given, regardless what type of tumor the patient has. We typically see these kinds of tumor-agnostic therapies more so in patients who have recurrent or advanced diseases in solid tumors. One monoclonal antibody example that comes to mind is dostarlimab. That's a checkpoint inhibitor that's approved for patients who are deficient in mismatch repair mechanism." TS 23:48 "Our immune system constantly has this surveillance system and it's able to recognize foreign pathogens, abnormal cells, and even precancerous cells. And they're able to eliminate them before they become cancerous. But on the flip side, one of the regulatory mechanisms that we have so our immune system doesn't attack itself is the presence of checkpoints. When these checkpoints bind to their ligands, this can then act as an off switch so that, again, our immune system is not going to attack itself. But then the tumor cells can take advantage of this and actually use this mechanism to evade the immune system. So, when we're giving a checkpoint inhibitor, now we're removing that off switch. As a consequence, common adverse effects can include things like immune mediated adverse events. These most commonly affect the skin, gastrointestinal tract, and liver. Essentially, this can cause any '-itis' you can think of." TS 26:36 "Looking at strategies to prevent infusion reactions, one example is the use of premedication. If premedication is recommended, this typically includes any combination of antipyretics, which is typically acetaminophen. Antihistamine, which is typically an H1 antagonist like diphenhydramine. Although, there could be cases where we want to substitute this agent because maybe the patient has been tolerating therapy okay, and they're having a lot of side effects. So, we might use a second-generation antihistamine in some cases. The premedication may be given with or without some kind of steroid, whether that's methylprednisolone, hydrocortisone, or dexamethasone." TS 29:53 "We tend to think of monoclonal antibody usage to be primary oncology, but that's not really the case. The first monoclonal antibodies that were developed were not for oncologic indications, they were for transplant indication for cardiac indication. So, they're really diversely utilized across all specialties and medicines. We have monoclonal antibodies for hyperlipidemia, for neurology, for rheumatology, so the uses are so very expansive across all specialties." TS 41:01
In this solo episode, Dr. Mike discusses the common issue of nocturia, where individuals frequently wake up at night to urinate, which disrupts sleep. The episode covers the root causes including sleep apnea, enlarged prostate, and overactive bladder, and dives into the roles of antidiuretic hormone (ADH) and atrial natriuretic peptide (ANP). It provides a comprehensive guide on addressing nocturia through behavioral modifications such as fluid restriction and sleep hygiene, supplements like pumpkin seed extract and beta-sitosterol, and pharmaceuticals including Desmopressin and alpha-blockers. The host also touches on treating sleep apnea with CPAP machines and mandibular advancement devices, emphasizing the importance of targeting the root cause for effective treatment. Links: CPAP (Continuous Positive Airway Pressure) Beta-Sitosterol Desmopressin (Synthetic ADH) Show Notes: 00:00 Understanding nocturia and its connection to sleep apnea 01:00 Introduction and episode overview 02:00 Defining nocturia and its impact on sleep 03:00 Types of nocturia and their causes 04:30 The role of hormones in nocturia 05:30 Sleep apnea and its effects on nocturia 15:30 Behavioral modifications to reduce nocturia 24:00 Supplements for managing nocturia 30:00 Pharmaceutical solutions for nocturia — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary. Beyond health science, we tackle the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
The US economy picked up speed over the three months to September, as consumer spending jumped and exports increased but consumer sentiment is low, Rahul Tandon hears from a business about what things are like on the ground. The US Food and Drug Administration (FDA) has approved a pill version of the weight-loss drug Wegovy, according to pharmaceutical giant Novo Nordisk. And, an important moment for Indian female cricket players seeing their match fees doubled for domestic games.(Photo: A person shops for products imported from Asia at a market in Los Angeles, California, USA, 07 April 2025. Credit: ALLISON DINNER/EPA-EFE/REX/Shutterstock)
Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.In a dynamic landscape marked by both advancements and challenges, the pharmaceutical and biotech sectors continue to evolve with notable scientific, regulatory, and strategic updates. Ipsen's recent $1 billion acquisition of Simcere's preclinical LRRC15-targeting asset underscores a growing focus on antibody-drug conjugates (ADCs). These conjugates leverage the targeted action of antibodies combined with the cytotoxic effects of drugs, representing a promising approach to cancer treatment by potentially minimizing systemic toxicity. Ipsen's strategic move reflects its commitment to expanding its oncology portfolio and staying competitive within the rapidly advancing ADC landscape.AstraZeneca has been active in its pursuit of innovative cancer treatments. The company has invested $100 million in Jacobio's clinical-stage pan-KRAS inhibitor, a promising development targeting KRAS mutations prevalent in various cancers. This investment aligns with AstraZeneca's strategy to tackle challenging oncogenic targets. However, their efforts faced a setback as their Phase 3 trial for ceralasertib, an ATR inhibitor for lung cancer, failed to meet its primary endpoint. Despite this setback, AstraZeneca maintains confidence by investing significantly in promising areas like KRAS inhibitors, highlighting the inherent risks involved in pioneering novel therapeutic strategies, particularly those aiming to overcome resistance mechanisms in immuno-oncology.BioMarin has quietly discontinued its liver disease candidate amid a $4.8 billion deal with Amicus. This decision points to the complex nature of pipeline prioritization and resource allocation within high-stakes financial environments. The company's strategic shifts reflect ongoing evaluations of their development priorities in light of evolving market demands.Boehringer Ingelheim has demonstrated a commitment to renal therapeutics with a $448 million investment in Rectify Pharmaceuticals for a preclinical chronic kidney disease program. This partnership seeks to address significant unmet medical needs within kidney disease treatment. Meanwhile, Gilead Sciences has entered into a $35 million licensing agreement with Assembly Biosciences for herpes simplex virus (HSV) assets, diversifying its infectious disease portfolio and expanding its reach within antiviral therapies.Novo Holdings-backed Windward Bio's acquisition of rights to Qyun's clinical-stage immunology bispecifics for $700 million highlights robust activity in the immunology space. Bispecific antibodies are gaining traction due to their ability to target two antigens simultaneously, offering enhanced therapeutic efficacy. This acquisition illustrates ongoing interest in this area as companies seek innovative solutions to complex immunological challenges.The broader industry is also witnessing strategic partnerships such as Aditum Bio's launch of a new biotech venture with Fosun Pharma. This collaboration aims to foster novel therapies through a synergistic blend of biotechnology innovation and pharmaceutical expertise. These alliances reflect an industry trend towards collaborative efforts that leverage diverse strengths to advance therapeutic development.In regulatory news, nine major pharmaceutical companies have reached agreements with the U.S. government to lower certain drug prices in exchange for tariff relief. This development signals ongoing negotiations aimed at balancing drug affordability with industry sustainability amid growing scrutiny over pricing practices.In December 2025, significant developments emerged, impacting scientific innovation, regulatory approvals, mergers, and strategic partnerships across the industry. Notably, the U.S. Food and Drug Administration (FDA) granted early approval to Cytokinetics' MyqorzSupport the show
Claire de Mézerville López welcomes Blair Kirby and Professor Mark Osler to the Restorative Works! Podcast. Blair and Mark join us to illuminate how restorative practices intersect with clemency work, storytelling, and systemic reform. Their conversation opens a window into the human impact of policies that often feel remote, revealing how small acts of recognition and repair can shift entire systems toward healing. Mark tells us about his commutation clinic at the University of St. Thomas School of Law, where he guides students as they uncover untold stories, meet directly with clients inside federal prisons, and learn how authentic narrative reshapes justice. Blair, a third-year law student and senior editor of the Journal of Law and Public Policy, brings her own lens as a former data analyst turned advocate. Her retelling of a first-degree murder clemency case, where three heartfelt apology letters were lost inside the corrections system, reveals how transparency and communication influence a victim's family's capacity to heal. Together, Mark and Blair describe how the commutation clinic operates at both the individual and systemic level, helping incarcerated people tell the fuller stories of their lives while also proposing legislative reforms that expand access to second chances. They highlight clients whose transformations demonstrate the power of rehabilitation, the role of narrative in restorative justice, and the responsibility of legal advocates to restore humanity, not simply file petitions. Blair grew up in South Korea and came to the US on her own at 15. After graduating from Macalester College with degrees in Applied Mathematics, Statistics, and Economics, she worked with government agencies, such as the Food and Drug Administration (FDA) and the Centers for Disease Control and Prevention (CDC) on epidemiology studies during the COVID-19 pandemic as a data and policy analyst in the Bay Area of California. She is currently a student at the University of St. Thomas School of Law (MN). Mark is the Robert and Marion Short Professor of Law at the University of St. Thomas, where he was chosen as Professor of the Year in 2016, 2019, and 2022. He also holds the Ruthie Mattox Preaching Chair at First Covenant Church, Minneapolis. His writing on clemency, sentencing, and narcotics policy has appeared in the New York Times, the Washington Post, and The Atlantic and in law journals at Harvard University, Stanford University, the University of Chicago, Northwestern, Georgetown, the University of Texas, Ohio State, UNC, William and Mary, and Rutgers. A former federal prosecutor, he won the case of Spears v. United States in the U.S. Supreme Court, with the Court ruling that judges could categorically reject the 100-to-1 ratio between crack and powder cocaine in the federal sentencing guidelines. Mark is a graduate of the College of William and Mary and Yale Law School. Tune in to discover how storytelling, advocacy, and courageous leadership move restorative justice from theory into action.
Government Accountability Office (GAO) Podcast: Watchdog Report
The Food and Drug Administration (FDA) is responsible for overseeing the safety of medical devices sold in the U.S. and issuing recalls when they're found to be unsafe. But recent headlines and high-profile lawsuits have drawn attention to the…
In this solo episode, Dr. Mike delves into the complex relationship between dopamine, romantic relationships, and the Coolidge Effect. The discussion highlights why men often feel the need for a new partner due to a desensitization of dopamine and how our overstimulated lifestyles contribute to this issue. The host explores the impact of modern habits on dopamine levels, the importance of boredom for resetting dopamine sensitivity, and the role of anticipation in maintaining desire. Practical solutions like dopamine resets, engaging in effort-based activities, and ensuring personal growth and solitude are discussed as ways to improve both individual well-being and relationship satisfaction. Links: The Dopamine Collapse Hypothesis: Foundations of Macro-Neuroeconomics Show Notes: 00:00 Welcome back to the Hart2Heart Podcast with Dr. Mike Hart 01:30 Understanding the dopamine cycle 03:30 Daily habits and dopamine desensitization 09:00 The Coolidge effect and relationship dynamics 15:00 Dopamine resets and effort-based activities 22:00 Reviving desire in long-term relationships 28:38 "Our nervous system never gets any time to recover—and that kills desire." — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary. Beyond health science, we tackle the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
In this episode, Dr. Mike Hart delves into the origins and contemporary relevance of the 10,000 steps rule. He discusses the latest research outcomes from a massive meta-analysis comparing daily step counts from 2,000 to 12,000 steps and their associated health benefits. Listeners will learn about the significant reductions in mortality, cardiovascular disease, cancer mortality, dementia, depression, and type 2 diabetes risk achieved by increasing daily steps. The episode also provides insights into the importance of breaking up sedentary periods, the physiological differences between various forms of steps, and practical tips for incorporating more steps into daily routines, even for office workers. Links: Massive Steps Meta-analysis Show Notes: (00:00) Welcome back to the Hart2Heart Podcast with Dr. Mike Hart (01:30) Origins of the 10,000 steps rule (03:00) Latest research on step counts (06:34) "Each 1,000 steps lowers your chance of depression by about 9%." (08:00) Steps vs. exercise: understanding the difference (21:30) Practical tips for increasing daily steps — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary. Beyond health science, we tackle the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Nationally recognized psychiatrist, internist, and addiction medicine specialist Muhamad Aly Rifai discusses his article, "The rise of digital therapeutics in medicine." Muhamad explains what prescription digital therapeutics (PDTs) are, emphasizing they are not wellness apps but Food and Drug Administration (FDA)-cleared, evidence-based software prescribed by clinicians to treat specific diagnoses. He explores the groundbreaking examples already authorized by the FDA, including software for substance use disorder, a video game for pediatric attention-deficit/hyperactivity disorder (ADHD), and a new adjunct treatment for major depressive disorder. Muhamad breaks down how these digital therapeutics are designed to work alongside (not replace) human clinicians, offering continuous, skill-building support for mental health conditions. Learn how this new category of medicine is moving care from the exam room into the patient's daily life and what it means for the future of treatment. Our presenting sponsor is Microsoft Dragon Copilot. Want to streamline your clinical documentation and take advantage of customizations that put you in control? What about the ability to surface information right at the point of care or automate tasks with just a click? Now, you can. Microsoft Dragon Copilot, your AI assistant for clinical workflow, is transforming how clinicians work. Offering an extensible AI workspace and a single, integrated platform, Dragon Copilot can help you unlock new levels of efficiency. Plus, it's backed by a proven track record and decades of clinical expertise, and it's part of Microsoft Cloud for Healthcare, built on a foundation of trust. Ease your administrative burdens and stay focused on what matters most with Dragon Copilot, your AI assistant for clinical workflow. VISIT SPONSOR → https://aka.ms/kevinmd SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended
"Antibody–drug conjugates (ADCs) have three basic parts: the antibody part, the cytotoxic chemo, and the linker that connects the two. First, the antibody part binds to the target on the surface of the cell. Antibodies can be designed to bind to proteins with a very high level of specificity. That's what gives it the targeted portion. Then the whole thing gets taken up by the cell and broken down, which releases the chemotherapy part. Some sources will call this the 'payload' or the 'warhead.' That's the part that's attached to the 'heat-seeking' part, and that's what causes the cell death," Kenneth Tham, PharmD, BCOP, clinical pharmacist in general oncology at the University of Washington Medicine and Fred Hutchinson Cancer Center in Seattle, WA, told Jaime Weimer, MSN, RN, AGCNS-BS, AOCNS®, manager of oncology nursing practice at ONS, during a conversation about antibody–drug conjugates. Music Credit: "Fireflies and Stardust" by Kevin MacLeod Licensed under Creative Commons by Attribution 3.0 Earn 0.5 contact hours of nursing continuing professional development (NCPD) by listening to the full recording and completing an evaluation at courses.ons.org by November 28, 2026. The planners and faculty for this episode have no relevant financial relationships with ineligible companies to disclose. ONS is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center's Commission on Accreditation. Learning outcome: Learners will report an increase in knowledge related to the mechanism of action of antibody–drug conjugates. Episode Notes Complete this evaluation for free NCPD. ONS Podcast™ episodes: Pharmacology 101 series Episode 303: Cancer Symptom Management Basics: Ocular Toxicities Episode 283: Desensitization Strategies to Reintroduce Treatment After an Infusion-Related Reaction ONS Voice articles: An Oncology Nurse's Guide to Cancer-Related Ocular Toxicities Antibody–Drug Conjugates Join the Best of Two Worlds Into One New Treatment Nursing Management of Adverse Events From Enfortumab Vedotin Therapy for Urothelial Cancer Oncology Nurses' Role in Translating Biomarker Testing Results The Pharmacist's Role in Combination Cancer Treatments ONS Voice drug reference sheets: Belantamab mafodotin-blmf Datopotamab deruxtecan-dlnk Enfortumab vedotin Fam-trastuzumab deruxtecan-nxki ONS book: Chemotherapy and Immunotherapy Guidelines and Recommendations for Practice (second edition) ONS course: ONS Fundamentals of Chemotherapy and Immunotherapy Administration™ Clinical Journal of Oncology Nursing articles: Antibody–Drug Conjugates and Ocular Toxicity: Nursing, Patient, and Organizational Implications for Care Nurse-Led Grading of Antineoplastic Infusion-Related Reactions: A Call to Action Other ONS resources: Antineoplastic Administration Huddle Card Biomarker Database Chemotherapy Huddle Card Monoclonal Antibodies Huddle Card Association of Cancer Care Centers (ACCC) antibody–drug conjugates page Drugs@FDA Hematology/Oncology Pharmacy Association (HOPA) National Cancer Institute cancer drugs page Network for Collaborative Oncology Development and Advancement (NCODA) clinical resource library ACCC/HOPA/NCODA/ONS Patient Education Sheets website To discuss the information in this episode with other oncology nurses, visit the ONS Communities. To find resources for creating an ONS Podcast club in your chapter or nursing community, visit the ONS Podcast Library. To provide feedback or otherwise reach ONS about the podcast, email pubONSVoice@ons.org Highlights From This Episode "The mechanism of action of the chemo itself depends on what agent or what 'warhead' is attached. Generally, [ADCs] have some kind of cytotoxic mechanism related to many of the chemotherapies that we use in practice, without attachment to the antibody. Some of them can be microtubule inhibitors, vinca alkaloids like vincristine. Some of them can be topoisomerase I (TOP1) inhibitors like irinotecan. Some can be alkylating agents that cause DNA breaks. So, again, looking back at the arsenal we have of cytotoxic chemo, these can all be incorporated into the ADCs." TS 5:54 "I want to talk about a case where the biomarker is being tested, but the biomarker isn't the target that you're looking for. One good case of this is a newer agent that was approved called datopotamab deruxtecan. The datopotamab portion is specific to a target called 'trophoblast cell surface antigen 2' (TROP2), which is expressed on the surface of many epithelial cancers. This agent was first approved in hormone receptor-positive, HER2-negative breast cancer, and received accelerated approval in patients with non-small cell lung cancer (NSCLC) with an EGFR mutation. ... The antibody looks for a target, TROP2. But in both of these cases—in the breast cancer and the NSCLC—you're testing for expression of different mutations or lack thereof. You're not looking for expression of TROP2. There's more research that needs to be done about the relationship between TROP2 expression and the presence or absence of these other biomarkers, but until we know more, we're actually testing for biomarkers that aren't the target of the ADC." TS 10:22 "There are common adverse advents to antibodies and chemo in general. Because we have both of these components, we want to watch out for the adverse effects of both of them. Antibodies, as with most proteins, can trigger an immune response or an infusion reaction. So, many ADCs can also cause hypersensitivity or infusion reactions. The rates of that are really variable and depend on the actual antibodies themselves. Then you have the cytotoxic component, the chemotherapy component, which has its own characteristic side effects. So, if we think of general chemo side effects—fatigue, nausea, bone marrow suppression, alopecia—these can [occur] with a lot of ADCs as well." TS 15:34 "The rate of ocular toxicity in [mirvetuximab soravtansine] is quite high. The manufacturer reports that this can occur in up to 60% of patients. With rates so high, the manufacturer recommends a preventive strategy. For this particular agent, [they] recommend patients have required eyecare. ... This ocular toxicity is something we do see in other ADCs that don't have the same target and don't necessarily have the same payload component. For example, tisotumab vedotin and again, datopotamab deruxtecan, can both cause ocular toxicities and both would have required ocular supportive care." TS 20:08 "Overall, I feel like the future is incredibly bright for these agents. There have only been around a dozen therapies approved by the U.S. Food and Drug Administration (FDA) despite this idea—the first agent came out in 2000. So, 25 years later, there are only around a dozen FDA-approved treatments. But there are so many more that are coming through the pipeline. And as we're discovering more biomarkers and developing more specialized antibodies, it's only natural that more ADCs will follow." TS 26:50
In this solo episode, the host discusses the effects of metformin, berberine, and dihydroberberine on exercise adaptation and longevity. While metformin is known for its longevity benefits and is popular in the biohacking community, it has been shown to significantly reduce exercise adaptations and VO2 max gains. Berberine, a supplement with similar effects to metformin, is easier to obtain but still has some negative effects on exercise and significant GI side effects. The episode introduces dihydroberberine (DHB), a compound with fewer GI issues and less impact on exercise adaptation, making it more suitable for athletes. The host explains the mechanisms behind these compounds, including their effects on AMPK and mTOR pathways, and offers practical advice on when to take DHB in relation to different types of exercise to maximize benefits and minimize drawbacks. Links: Harvard longevity researcher known for NAD+ & aging research. Diabetes drug often discussed for longevity.Energy-sensing enzyme that promotes catabolic (fat-burning) pathways. Show Notes: 00:00 Welcome back to the Hart2Heart Podcast with Dr. Mike Hart 00:14 "Metformin may blunt up to 50% of your VO₂ max gains — that's a massive hit for any athlete." 00:30 Metformin: the popular longevity drug 01:00 Berberine: the over-the-counter alternative 02:30 Understanding AMPK and mTOR 04:30 Metformin's mechanism and drawbacks 06:00 Berberine's mechanism and side effects 07:30 Dihydro berberine: the superior choice 10:30 DHB and exercise: timing and benefits 18:00 Comparing Metformin, berberine, and DHB — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary. Beyond health science, we tackle the intersection of public health and politics, exposing how policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Jay Berglind is a nationally respected food safety expert and the principal of Aegis Foods, a consultancy focused on strengthening food safety systems across the supply chain. Aegis Foods is also the maker of Fearless Eggs, the only pasteurized in-shell and poached eggs that are safe to eat raw. With more than 25 years of experience in food manufacturing, regulatory compliance, and quality assurance, Jay is a trusted voice on preventing foodborne illness, understanding federal regulations, and responding to product recalls. Jay has served in leadership roles overseeing food safety and quality programs for major U.S. food manufacturers. His expertise spans U.S. Department of Agriculture (USDA) and U.S. Food and Drug Administration (FDA) inspection standards, Hazards Analysis and Critical Control Points (HACCP), and third-party audit preparation. Through Aegis Foods, he now advises clients on building proactive, recall-resistant systems that prioritize both consumer health and brand integrity. In this episode of Food Safety Matters, we speak with Jay [38:36] about: The history of Jay's career and how his experiences led to the creation of Fearless Eggs The science behind the pasteurization method used by Fearless Eggs and how it differs from traditional shell egg pasteurization, as well as Fearless Eggs' latest innovation, the in-shell poached egg How Fearless Eggs' pasteurization method inactivates Salmonella and other food safety hazards like avian influenza The process of working with FDA to get Fearless Eggs' pasteurization method approved The consumer trust built not only by Fearless Eggs' pasteurization, but also its prioritization of food safety Jay's perspective on the Trump Administration's resource and staffing cuts to FDA and the effect on consumer confidence in the safety of the U.S. food supply How Aegis and Fearless Eggs are helping move the entire industry toward safer egg products and food safety innovation Where to find Fearless Eggs products. News and Resources News ByHeart Outbreak Grows: 31 Infants in 15 States Hospitalized for Botulism From Tainted Formula [4:29] ByHeart Formula Now Linked to 23 Infant Botulism Cases in 13 States Infants Nationwide Hospitalized With Botulism After Consuming ByHeart Formula Regan-Udall Report Supports FDA Infant Formula Safety Efforts [16:16] Analysis Shows FDA Foreign Facility Inspections Hit Historic Low After Trump Admin Cuts [23:02] First-of-its-Kind Study Shows How Listeria Strains Evolve Into Strong Biofilm Formers [31:44] FAO Report Highlights Needs for Responsible AI Adoption in Food Safety Fields [35:01] Resources Webinar: Dry Sanitation and Cleaning Techniques for Facilities and Equipment We Want to Hear from You! Please send us your questions and suggestions to podcast@food-safety.com
This episode covers: • Nano CBD Pain Relief Without Cognitive Side Effects A new nano-micelle formulation of CBD called CBD-IN delivers fast, non-addictive pain relief in mice without memory issues, motor impairment or the usual cannabinoid “fog.” Because it crosses the blood brain barrier and directly targets hyperactive pain circuits, it sidesteps many opioid-type drawbacks. Dave explains why precision-designed cannabinoids could reshape chronic pain treatment and longevity support. Source: https://www.sciencedaily.com/releases/2025/11/251117095652.htm • Moderate Calorie Restriction Slows Biological Aging A long-term trial from the National Institute on Aging found that cutting calories by about 12% over two years slowed the pace of aging — measured by methylation clocks and metabolic markers — in lean and mildly overweight adults alike. Dave breaks down why small, manageable dietary tweaks can deliver big longevity gains, without crash dieting or extreme fasting. Source: https://www.nia.nih.gov/news/cutting-calories-may-slow-pace-aging-healthy-adults • FDA Approves AI-Guided Robotic Surgery Trials for Alzheimer's The U.S. Food and Drug Administration (FDA) has granted IDE approval for the first robotic microsurgical study targeting early stage Alzheimer's disease using AI and deep imaging. The trial uses adaptive robotics to target deep brain lymphatic pathways, potentially clearing amyloid/tau deposits with surgical precision. Dave explains why this signals a new era in neurodegeneration – moving from drug-only to machine-assisted brain repair. Source: https://www.mmimicro.com/ide-approval-for-first-robotic-microsurgery-alzheimers-study/ • Antibiotic Reprograms Gut Bacteria to Produce Anti-Aging Molecules Researchers demonstrated that the veterinary antibiotic cephaloridine can reprogram gut microbes to secrete colanic acid — a molecule linked to better mitochondrial health, reduced gut permeability and improved cholesterol/insulin balance in mice. Dave explores how this could evolve into a pipeline of engineered probiotics that act as internal “longevity factories.” Source: https://newatlas.com/aging/antibiotic-longevity-microbiome/ (link remains unchanged) • Klotho: The Longevity Protein Nears Clinical Reality The longevity protein Klotho, known for clearing toxic by-products, calming inflammation and protecting brain/organ networks, is now advancing toward human trials via injectables, oral formats and gene therapy. Dave explains why Klotho is shaping up as a foundational target for next-gen age-reversal strategies and stacking protocols. Source: https://investingnews.com/longevity-focused-health-fueling-u-s-anti-aging-products-market-projected-to-reach-27-billion-by-2033/ (link remains unchanged) All source links provided for easy reference to the original reporting and research above. This episode is essential listening for fans of biohacking, human performance, functional medicine and longevity who want practical tools from Host Dave Asprey and the latest breakthroughs shaping the future of health. Dave Asprey is a four-time New York Times bestselling author, founder of Bulletproof Coffee, and the father of biohacking. With over 1,000 interviews and 1 million monthly listeners, The Human Upgrade gives you the knowledge to take control of your biology, extend your longevity, and optimize every system in your body and mind. Each episode delivers cutting-edge insights in health, performance, neuroscience, supplements, nutrition, biohacking, emotional intelligence and conscious living. New episodes are released every Tuesday, Thursday, Friday (audio only) and Sunday (BONUS). Dave asks the questions no one else will and gives you real tools to become stronger, smarter, and more resilient. Keywords: nano CBD, CBD-IN, pain relief research, non opioid pain therapies, chronic pain and aging, caloric restriction aging, methylation clocks, metabolic resilience, AI robotics, Alzheimer's microsurgery, neurotech advancement, microbiome engineering, colanic acid, longevity probiotics, mitochondrial support, Klotho protein, anti aging gene therapy, cellular rejuvenation, longevity news, biohacking updates Thank you to our sponsors! LYMA | Go to https://lyma.sjv.io/gOQ545 and use code DAVE10 for 10% off the LYMA Laser. Vibrant Blue Oils | Grab a full-size bottle for over 50% off at https://vibrantblueoils.com/dave. Resources: • Subscribe to my weekly newsletter: https://substack.daveasprey.com/welcome • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Upgrade Collective: https://www.ourupgradecollective.com • Upgrade Labs: https://upgradelabs.com • 40 Years of Zen: https://40yearsofzen.com Timestamps: 0:00 — Intro 0:19 — Story 1: Nano CBD for Pain Relief 1:53 — Story 2: Caloric Restriction and Aging 3:20 — Story 3: AI Robotic Surgery for Alzheimer's 4:50 — Story 4: Microbiome Reprogramming 6:05 — Substack Announcement 7:04 — Story 5: Klotho Longevity Protein 8:39 — Weekly Homework 9:31 — Outro See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
In this episode of the Heart to Heart podcast, Dr. Mike Hart chats with Tony Ricci, an athletic performance and mental health coach for athletes. Tony shares his fascinating journey from studying exercise physiology to working with elite athletes like MMA fighter Chris Weidman. They discuss the critical impact of mental resilience on athletic performance, practical strategies for mental and physical training, and bridging the gap between nutrition, conditioning, and mental skills training. Additionally, the conversation touches on the role of technology like HRV and sleep tracking in athlete performance, effective supplement strategies, and the nuanced benefits of practices like cold plunges and saunas. Tony also reflects on adjustments he has made in his training approach over the years to avoid overtraining fighters. Tony Ricci is a veteran performance coach and sport scientist specializing in the intersection of strength training, nutrition, and mental performance for combat athletes. With a background spanning exercise physiology, sports science, and nutrition—as well as decades of hands-on coaching—Tony has trained world-class fighters and helped shape modern approaches to MMA preparation. Connect with Tony on Instagram at sportpsy_sci_doc or at tony@fightshape.net Links: Chris Weidman Creatine for Neuroprotection & Brain Health Beetroot/Nitrate Supplementation for endurance Zone 2 Training & Mitochondrial Biogenesis Show Notes: 00:00 Welcome back to the Hart2Heart podcast with Dr. Mike Hart 00:30 Tony Ricci's background in athletic performance 02:00 The importance of mental performance in sports 04:30 Strategies for mental resilience in athletes 09:00 Psychological resilience and childhood experiences 13:02 "Yes, you can still build mental toughness without trauma. Many champions had good parents, good support, and still developed world-class grit." 14:30 Discipline: self-trained vs. innate 18:00 Using technology to monitor athlete performance 31:30 Handling poor sleep before a big fight 33:30 The role of caffeine in training camps 35:30 Creatine usage and dosage 37:30 Recommended supplements for athletes 39:30 Beta-alanine and its benefits 43:30 Exploring other supplements: beetroot, HMB, and Alpha GPC 48:00 Exogenous ketones and ketogenic diets 54:00 The benefits of cold plunges and saunas 58:00 Evolving training methods for fighters 01:00:30 Optimizing cardio training for fighters — The Hart2Heart podcast is hosted by family physician Dr. Michael Hart, who is dedicated to cutting through the noise and uncovering the most effective strategies for optimizing health, longevity, and peak performance. This podcast dives deep into evidence-based approaches to hormone balance, peptides, sleep optimization, nutrition, psychedelics, supplements, exercise protocols, leveraging sunlight light, and de-prescribing pharmaceuticals—using medications only when absolutely necessary. Beyond health science, we tackle the intersection of public health and politics, exposing how Policy decisions shape our health landscape and what actionable steps people can take to reclaim control over their well-being. Guests range from out-of-the-box thinking physicians such as Dr. Casey Means (author of "Good Energy") and Dr. Roger Sehult (Medcram lectures) to public health experts such as Dr. Jay Bhattacharya (Director of the National Institutes of Health (NIH) and Dr. Marty Mckary (Commissioner of the Food and Drug Administration (FDA) and high-profile names such as Zuby and Mark Sisson (Primal Blueprint and Primal Kitchen). If you're ready to take control of your health and performance, this is the podcast for you. We cut through the jargon and deliver practical, no-BS advice that you can implement in your daily life, empowering you to make positive changes for your well-being. Connect on social with Dr. Mike Hart: Instagram: @drmikehart Twitter: @drmikehart Facebook: @drmikehart
Forever Young Radio Show with America's Natural Doctor Podcast
Cavities are still one of America's most common diseases – despite decades of fluoride use. Xlear is calling on the FDA to recognize xylitol as an active anticaries ingredient so dental professionals and patients can finally access this powerful tool. Xylitol, a safe and natural compound, has been proven to stop cavity- causing bacteria and dramatically reduce tooth decay.The American Dental Hygienist Association (ADHA) in conjunction with Xlear, a leader in hygiene products, filed a citizen petition with the U.S. Food & Drug Administration (FDA) urging the FDA to formally recognize xylitol as an approved Over-the-Counter (OTC) active ingredient in dental hygiene products, including toothpaste, rinses, gels, mouthwashes, gums, and lozenges.Xylitol addresses the root cause of tooth decay. In contrast, fluoride strengthens tooth enamel. Fluoride has almost no effect on the bacteria that causes tooth decay. Studies have shown that xylitol has a higher “protection factor” in fighting cavities than fluoride.“Dental decay is the single most common communicable, chronic disease inflicting Americans today. Moreover, dental decay is also closely associated with driving other serious health risks - ranging from heart disease to diabetes,” said Trisha O'Hehir, MS, RDH.Key Facts:· Nearly 90% of U.S. adults have experienced tooth decay.· Studies show xylitol can reduce cavities by up to 80%.· Xylitol works by neutralizing acid-producing bacteria and protecting enamel at the source.· Xylitol is safe if swallowed, a key benefit for children.· Widely used internationally, xylitol is already found in gum and oral hygiene products. The petition requests that FDA: Amend 21 C.F.R. Part 355 to list xylitol as an approved anti-caries active ingredient. Alternatively, issue a new OTC monograph under Section 505G of the FDCA.Learn more about the Petition hereXlear is one of the nation's leaders in effective xylitol hygiene products, available inpharmacies, big box stores, natural retailers and online.XLEAR's Retailers: Walgreens, CVS, Vitamin Shoppe, Target, Kroger, Sprouts, Natural Grocers and most natural products retailers nationwide.XLEAR's Online Retailers: Amazon, iHerb, Lucky Vitamin, and Vitacost.comLearn more at Xlear.com or SprySmile.com
Elinzanetant, sold under the brand name Lynkuet, receivedapproval from the U.S. Food and Drug Administration (FDA) on October 24, 2025, for the treatment of moderate to severe hot flashes due to menopause. How is this different than Fezolinetant, which was approved in 2023? Listen in for details. 1. Menegaz de Almeida, Artur MS; Oliveira, Paloma MS; Lopes, Lucca MD; Leite, Marianna MS; Morbach, Victória MS; Alves Kelly, Francinny MD; Barros, Ítalo MS; Aquino de Moraes, Francisco Cezar MS; Prevedello, Alexandra MD. Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms: A Systematic Review and Meta-analysis. Obstetrics & Gynecology 145(3):p 253-261, March 2025. | DOI: 10.1097/AOG.00000000000058122. Pinkerton JV, Simon JA, Joffe H, Maki PM, NappiRE, Panay N, Soares CN, Thurston RC, Caetano C, Haberland C, Haseli Mashhadi N, Krahn U, Mellinger U, Parke S, Seitz C, Zuurman L. Elinzanetant for the Treatment of Vasomotor Symptoms Associated With Menopause: OASIS 1 and 2 Randomized Clinical Trials. JAMA. 2024 Aug 22;332(16):1343–54. doi: 10.1001/jama.2024.14618. Epub ahead of print. PMID: 39172446; PMCID: PMC11342219.3. Cardoso F, Parke S, Brennan DJ, Briggs P,Donders G, Panay N, Haseli-Mashhadi N, Block M, Caetano C, Francuski M, Haberland C, Laapas K, Seitz C, Zuurman L. Elinzanetant for Vasomotor Symptomsfrom Endocrine Therapy for Breast Cancer. N Engl J Med. 2025 Aug 21;393(8):753-763. doi: 10.1056/NEJMoa2415566. Epub 2025 Jun 2. PMID: 40454634.STRONG COFFEE PROMO: 20% Off Strong CoffeeCompany https://strongcoffeecompany.com/discount/CHAPANOSPINOBG
Essential oils are concentrated plant extracts obtained through distillation and pressing. This process captures the aromatic compounds responsible for the oils' fragrance and therapeutic effects The U.S. Food and Drug Administration (FDA) designates some oils as Generally Recognized as Safe (GRAS), meaning food-grade oils are safe to ingest in tiny amounts GRAS essential oils like peppermint, lemon, ginger, cinnamon, and basil can be used to flavor foods and beverages. This reflects their culinary value when used sparingly Other essential oils, such as lavender, eucalyptus, tea tree, rosemary, chamomile, wintergreen, and camphor, are best suited for aromatic or topical use Whether in food, through scent, or applied to the skin, essential oils support wellness when used with care and intention
© 2020-2026 Ivy Podcast Discovery LLC
